PEER Systematic Review of Randomized Controlled Trials: Management of Chronic Low Back Pain in Primary Care Appendix 2

Michael R. Kolber, Joey Ton, Betsy Thomas, Jessica Kirkwood, Samantha Moe, Nicolas Dugre, Karenn Chan, Adrienne J Lindblad, James McCormack, Scott Garrison, G. Michael Allan, Christina Korownyk, Rodger Craig, Logan Sept, Michael Wollin, Andrew Rouble, Danielle Perry

Table of Contents

Table 1: Low Back Pain Outcomes Hierarchy	7
Table 2: Included Randomized Controlled Trials)
Table 3: Overall proportion of patients with meaningful response and proportion at less than or equal to four weeks, four to twelve weeks and at greater than twelve weeks	7
Table 4: Overall proportion of patients with meaningful response at longest follow-up point after intervention	3
Table 5: Proportion of patients with clinically meaningful response based on funding source (clearly publicly or industry funding)19	;
Table 6: Proportion of patients with clinically meaningful response based on median risk of timeseesee	9 n at less than 17 ow-up point 18 oding source 19 dian risk of 20 21 response to 21 response to 22 response to 22 response to 22 response to 22 response to 22 response to 22 response to 22 response to 23 eaningful 23 eaningful 23 eaningful 23 eaningful 25 response to 25 response to 26 response to 26 response to 27 27 28 29 29 20 20 20 21 20 22 22 22 22 22 22 22 22 23 23
bias scores	'
Data Analysis	l
Exercise	
Figure 1.1: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment	
Figure 1.2: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to	
treatment at 4 weeks or less22	<u>)</u>
Figure 1.3: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks	
Figure 1.4: Exercise versus	2
Figures 1.5: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response at longest follow up time	2
Figures 1.6: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful	,
response to treatment, analyzed by study funding source (public or industry funding)	3
Figures 1.7: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful	
response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score)24	ļ
Acupuncture	;
Figure 2.1: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to	_
treatment)
Figure 2.2: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less	5
Figure 2.3: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks	
Figure 2.4: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater	
Figure 2.5: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response at longest follow up time	5
Figure 2.6: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful	
response to treatment, analyzed by study funding source (public or industry funding)2	'
Figure 2.7: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful	
response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score)2	1
Spinal Manipulation28	3

	Figure 3.1: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment
	Figure 3.2: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less. (Post hoc analysis)
	Figure 3.3: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response
	to treatment at greater than 4 weeks and less than 12 weeks
	(Post hoc analysis)
	Figure 3.4: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response
	to treatment at 12 weeks or greater. (Post hoc analysis)
	Figure 3.5: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response at longest follow up time
	Figure 3.6: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)29
	Figure 3.7: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater
	than or equal to the median risk of bias score) (post hoc analysis)
_	
O	al NSAIDs
	Figure 4.1: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment
	Figure 4.2: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment at 4 weeks or less. (Post hoc analysis)31
	Figure 4.3: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment at greater than 4 weeks and less than 12 weeks. (Post hoc analysis)
	Figure 4.4: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment at 12 weeks or greater. (Post hoc analysis)
	Figure 4.5: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)32
	Figure 4.6: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater
	than or equal to the median risk of bias score) (post hoc analysis)
Rι	ıbefacients
	Figure 5.1: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment
	Figure 5.2: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment at 4 weeks or less. (Post hoc analysis)
	Figure 5.3: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)33
	Figure 5.4: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaningful
	response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater
	than or equal to the median risk of bias score) (post hoc analysis)
0	pioids
	Figure 6.1: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment35
	Figure 6.2: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response to
	treatment at 4 weeks or less. (Post hoc analysis)
	Figure 6.3: Opioids versus placebo; Outcome: Outcome: Proportion of patients with a meaningful response
	to treatment at 12 weeks or greater. (Post hoc analysis)
	Figure 6.4: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to
	treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

Figure 6.5: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful treatment, analyzed by median risk of bias (less than the median risk of bias score or greater that the median risk of bias score) (post hoc analysis)	an or equal to
SNRIs	
Figure 7.1: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningf	
to treatment	
Figure 7.2: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningf to treatment at 12 weeks or greater. (Post hoc analysis)	-
Figure 7.3: SNRIs (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a r	neaningful
response to treatment, analyzed by study funding source (public or industry funding) (Post hoc a	• •
Figure 7.4: SNRIs (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a r	-
response to treatment, analyzed by median risk of bias (less than the median risk of bias score of	-
than or equal to the median risk of bias score) (post hoc analysis)	38
Corticosteroid Injections	
Figure 8.1: Corticosteroid injections versus saline injections; Outcome: Proportion of patients wi	
meaningful response to treatment.	
Figure 8.2: Corticosteroid injections versus saline injections; Outcome: Proportion of patients wi	
meaningful response to treatment at 4 weeks or less	
Figure 8.3: Corticosteroid injections versus saline injections; Outcome: Outcome: Proportion of	
a meaningful response to treatment at 12 weeks or greater	
Figure 8.4: Corticosteroid injections versus saline injections; Subgroup analysis: Proportion of pa	
meaningful response to treatment, analyzed by study funding source (public or industry funding	
Figure 8.5: Corticosteroid injections versus saline injections; Subgroup analysis: Proportion of pa	
meaningful response to treatment, analyzed by median risk of bias (less than the median risk of	bias score or
greater than or equal to the median risk of bias score)	40
ost Hoc Analysis	41
I. Fixed Effects Analysis	/1
Figure 9.1: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful resp	
treatment (fixed effects analysis)	
Figure 9.2: Acupuncture versus control; Outcome: Proportion of patients with a meaningful resp	
treatment (fixed effects analysis)	
Figure 9.3: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaning	
to treatment Oral NSAIDs (fixed effects analysis)	
Figure 9.4: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful resp	
treatment (fixed effects analysis)	
Figure 9.5: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful res	
treatment (fixed effects analysis)	
Figure 9.6: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response	
treatment (fixed effects analysis)	
Figure 9.7: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningf	
to treatment (fixed effects analysis)	
Figure 9.8: Corticosteroid injections versus saline injections; Outcome: Proportion of patients wi	
meaningful response to treatment (fixed effects analysis)	
II. Subgroup analysis by control group characteristics (sham versus non-sham procedu	ires or
II. Subgroup analysis by control group characteristics (sham versus non-sham procedu prescribed versus passive exercise controls)	
II. Subgroup analysis by control group characteristics (sham versus non-sham procedu prescribed versus passive exercise controls) Figures 10.1: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a mean	45

Figure 10.2: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by control group characteristics (sham versus non-sham procedures).......46 Figure 10.3: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by control group characteristics (sham versus non-sham procedures).......46

III. Subgroup analysis by trial size	47
Figures 11.1: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningfu	ıl
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	47
Figures 11.2: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningfo	ul
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	48
Figures 11.3: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a me	eaningful
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	48
Figures 11.4: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningfu	ul
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	49
Figures 11.5: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaning	ful
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	49
Figures 11.6: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful res	sponse
to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	50
Figures 11.7: SNRI (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a mea	ningful
response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)	
Figures 11.8: Corticosteroid Injections versus saline injections; Subgroup analysis: Proportion of patie	ents with
a meaningful response to treatment, analyzed by study size (<150 participants compared to ≥150	
participants)	51
Adverse Events	52
Table 7: Overall Adverse Events	52
Data Analysis of Adverse Events	69
-	
Oral NSAIDs	
Figure 12.1 Oral NSAIDs versus placebo; Withdrawals due to Adverse Events	
Figure 12.2 Oral NSAIDs versus placebo; Serious Adverse Events	
Figure 12.3 Oral NSAIDs versus placebo; Adverse Event: Edema	
Figure 12.4 Oral NSAIDs versus placebo; Adverse Event: Headache	
Figure 12.5 Oral NSAIDs versus placebo; Adverse Event: Upper Respiratory Infection	69
Rubefacients	69
Figure 13.1 Rubefacients versus placebo; Adverse Event: Heat Sensation	69
Figure 13.2 Rubefacients versus placebo; Adverse Event: Pruritus	69
Opioids	69
Figure 14.1 Opioids versus placebo; Withdrawals due to Adverse Events	69
Figure 14.2 Opioids versus placebo; Serious Adverse Events	70
Figure 14.3 Opioids versus placebo; Adverse Event: Constipation	70
Figure 14.4 Opioids versus placebo; Adverse Event: Diarrhea	70
Figure 14.5 Opioids versus placebo; Adverse Event: Dizziness	70
Figure 14.6 Opioids versus placebo; Adverse Event: Dry Mouth	70
Figure 14.7 Opioids versus placebo; Adverse Event: Dyspepsia	
Figure 14.8 Opioids versus placebo; Adverse Event: Fatigue	71
Figure 14.9 Opioids versus placebo; Adverse Event: Headache	71
Figure 14.10 Opioids versus placebo; Adverse Event: Hyperhydrosis	71
Figure 14.11 Opioids versus placebo; Adverse Event: Insomnia	72
Figure 14.12 Opioids versus placebo; Adverse Event: Nausea	72
Figure 14.13 Opioids versus placebo; Adverse Event: Pruritis	72

Figure 14.14 Opioids versus placebo; Adverse Event: Somnolence	72
Figure 14.15 Opioids versus placebo; Adverse Event: Vomiting	73
SNRI (Duloxetine)	
Figure 15.1 SNRI (Duloxetine) versus placebo; Withdrawals due to Adverse Ev	
Figure 15.2 SNRI (Duloxetine) versus placebo; Serious Adverse Events	
Figure 15.3 SNRI (Duloxetine) versus placebo; Adverse Event: Constipation	
Figure 15.4 SNRI (Duloxetine) versus placebo; Adverse Event: Dizziness	
Figure 15.5 SNRI (Duloxetine) versus placebo; Adverse Event: Dry Mouth	
Figure 15.6 SNRI (Duloxetine) versus placebo; Adverse Event: Nausea	
Funnel Plots	
Funnel plots were generated via RevMan for interventions with ≥8 stud	ies. This information was
used in the GRADE process to assess potential publication bias	75
Figure 17.1 Exercise studies	
Figure 17.2 Acupuncture studies	75
Figure 17.3 Corticosteroid Injection studies	76
Quality Assessment	
Cochrane Risk of Bias tables	
Risk of Bias Assessment	Error! Bookmark not defined.
Table 8.1 Exercise	
Table 8.2 Acupuncture	
Table 8.3 Spinal manipulation	79
Table 8.4 Oral NSAIDs	79
Table 8.5 Rubefacients	80
Table 8.6 Opioids	80
Table 8.7 SNRI (Duloxetine)	
Table 9: GRADE Evaluation of Evidence Quality	
Peer Review Comments/Feedback	
References	

Table 1: Low Back Pain Outcomes Hierarchy

- This hierarchy outlines the priority of outcomes used for overall meta-analyses presented in the systematic review.
- When there are studies that report a scale change on: Pain only or pain and function, we would prefer to use assessments on pain only. We are not including assessments or responder analyses that only focus on function.
 - **Rationale:** As clinicians we understand function is crucial however, we also know that pain is the presenting issue for patients. Therefore, we wanted to develop information around pain to allow for shared decision-making with our patients.
- 1. Percent improvement on a pain scale that is closest to 30% improvement
 - a. If there is a tie, eg. 25% and 35% improvement, we would use the higher number.
- 2. Clinically meaningful change on any low back pain scale (e.g. Minimally Clinical Important Change on a Roland Morris Back Pain Scale)
 - a. This includes achieving a particular back pain scale score that reaches a certain threshold on the low back pain scale at the study endpoint.
- 3. Change of **at least** 1 on a VAS / NRS scale (out of 11 or 10); Or change of ≥10 on a VAS/NRS (out of scale 100).
 - a. If multiple outcomes included are reported, order of preference is:
 - ≥2 change on VAS/NRS out of 10-11 or change of ≥20 on VAS/NRS out of 100.
 - ii. ≥3 change on VAS/NRS out of 10-11 or change of ≥30 on VAS/NRS out of 100.
 - iii. \geq 1 change on VAS / NRS out of 10-11 or change of \geq 10 on VAS / NRS out of 100.

Note: Change of at least 2 is preferred because if an average baseline pain of 5-6 is seen, a change of 2 would be closest to a 30% improvement in change.

- 4. Reaching a score of ≤4 on VAS / NRS scale (out of 11 or 10); Or score of ≤40 on a VAS/NRS (out of scale 100).
 - a. If multiple is present, order of preference is:
 - Reaching a score of ≤4 on VAS / NRS scale (out of 11 or 10); Or score of ≤40 on a VAS/NRS (out of scale 100).
 - Reaching a score of ≤3 on VAS / NRS scale (out of 11 or 10); Or score of ≤30 on a VAS/NRS (out of scale 100).
 - iii. Reaching a score of ≤2 on VAS / NRS scale (out of 11 or 10); Or score of ≤20 on a VAS/NRS (out of scale 100).
 - iv. Reaching a score of ≤ 1 on VAS / NRS scale (out of 11 or 10); Or score of ≤ 10 on a VAS/NRS (out of scale 100).

Note: Reaching a score of <4/10 is preferred because if an average baseline pain of 5-6/10 is seen, obtaining a score of 4 or less would be closest to a 30% improvement in change.

- 5. Change in a scale that are out of a score not mentioned above (example out of 20). (We will have to adjust so it comes close to that 30% improvement.)
- 6. Patient Global Assessment of Change / Improvement (eg. None/Slight/Moderate/Very Good/Excellent (or similar language).
 - a. If multiple outcomes involving the assessment is available or calculatable, preference is:
 - i. Patients achieving at least a **moderate/good** (or similar wording) or greater change.
 - ii. Patients achieving at least a **very good** (or similar wording) or greater change.
 - iii. Patients achieving at least an **excellent** (or similar wording) or greater change.
 - b. Notes:
 - i. We are not including caregiver or clinician assessment of change.
 - ii. If there is an undefined % improved as determined by **patient** we would include.
 - iii. There may be times when authors need to combine raw event numbers to obtain the above pre-specified outcomes, this would occur following data extraction step.

Table 2: Included Randomized Controlled Trials

Interventions are listed in alphabetical order.

Intervention Type	Author, Year	Sample Size	Duration of Back Pain (weeks)	Mean Age	Outcome Measured At	Intervention(s), Comparator(s)	Outcome used in Meta-Analysis
Acupuncture	Brinkhaus 2006	219	764 weeks	59	8 weeks	Acupuncture; 12, 30-minute sessions Minimal Acupuncture; 12, 30-minute sessions	At least 50% reduction in pain intensity
Acupuncture	Cherkin 2009	638	Not reported	47	8 weeks	Individualized acupuncture; 10 sessions Standardized Acupuncture; 10 sessions Simulated Acupuncture; 10 sessions Usual Care including self-help book	Proportion of patients with MCID in pain (decrease in symptom bothersome scale by 2 or greater)
Acupuncture	Coan 1980	50	468 weeks	47	10 weeks	Acupuncture Waitlist	PGIC rated "improved" (decrease in <u>></u> 2 on 10- point scale)
Acupuncture	Haake 2007	1162	395 weeks	49	24 weeks	Verum Acupuncture; 10, 30-minute sessions Sham Acupuncture; 10, 30-minute sessions	33% or greater improvement on 3 pain-related items on the Von Korff Chronic Pain Grade Scale or 12% improvement or greater on back- specific functional status measured by the Hanover Functional Ability Questionnaire
Acupuncture	Hunter 2011	51	515 weeks	43	24 weeks	Auricular Acupuncture; provided prior to each exercise class and to be removed in 48 hours + Exercise (see below) Exercise; physiotherapy-delivered for 6 weeks followed by 6 weeks of unsupervised exercise	Proportion of patients achieving a MCID (8% change on Oswestry Disability Questionnaire)
Acupuncture	Kerr 2003	60	303 weeks	41	24 weeks	Acupuncture; 6, 30-minute sessions Placebo-TENS (no elec); 6, 30-minute sessions	Proportion of patients who experienced pain relief

Acupuncture	Meng 2003	51	624 weeks	71	6 weeks	Acupuncture + Standard Therapy; 10 sessions Standard Therapy	PGIC rated "much better"
Acupuncture	Molsberger 1998	186	515 weeks	50	4 weeks	Verum Acupuncture + Conventional Orthopedic Therapy (see below) Sham + Conventional Orthopedic Therapy; 12, 30-minute sessions	50% reduction in VAS
Acupuncture	Qin 2019	80	Not reported	62	8 weeks	Acupuncture; 24, 30-minute sessions Sham Acupuncture; 24, 30-minute sessions	Proportion of patients with a 30% or more improvement in Roland Morris Disability Questionnaire
Acupuncture	Witt 2006	2841	374 weeks	53	12 weeks	Acupuncture; maximum 15 sessions Waitlist	Proportion of patients who improved \geq 20% in "back function loss")
Anticonvulsants	Atkinson 2016	108	910 weeks	56	12 weeks	Gabapentin (mean 3265 mg) Placebo	30% Improvement in Pain
Corticosteroid Injections	Arden 2005	228	NR	44	52 weeks	Corticosteroid Injections (Weeks 0,3,6) Saline Injections (Weeks 0,3,6)	≥75% improvement in Oswestry Disability Questionnaire
Corticosteroid Injections	Carette 1997	158	13 weeks	40	12 weeks	Epidural Corticosteroid (methylprednisolone) Injections (Up to 3) – Could be at 0,3,6 weeks and depended if no marked improvement or Oswestry Disability Questionnaire >20 seen. Saline Injections - Could be at 0,3,6 weeks	Oswestry Disability Questionaire <u><</u> 20 points
Corticosteroid Injections	Ghahreman 2010	23	67 weeks	45	4 weeks	Bupivacine 0.5% followed with Corticosteroi Injection (Triamcinolone) – (Up to 3 injections, repeat injections offered if 1 st thought to be beneficial) Bupivacaine 0.5% (Up to 3 injections, repeat injections offered if 1 st thought to be beneficial)	≥50% improvement 1 month after treatment

Corticosteroid Injections	Ghai 2015	69	82 weeks	45	52 weeks	Lidocaine 0.5% mixed with Corticosteroid Injection (Methylprednisolone) – Multiple Injections Offered if deterioration of pain relief was <50% - Need to be spaced at least 15 days apart Lidocaine 0.5% Only - Multiple Injections Offered if deterioration of pain relief was <50% - Need to be spaced at least 15 days apart	≥50% improvement from baseline
Corticosteroid Injections	Manchikanti 2012	100	399 weeks	56	52 weeks	Epidural Injections (Lidocaine 0.5% mixed with Betamethasone) – multiple injections offered Lidocaine 0.5% Only – multiple injections offered	≥50 pain relief and functional status improvement
Corticosteroid Injections	Manchikanti 2012a	120	384 weeks	46	104 weeks	Lidocaine 0.5% mixed with Corticosteroid Injection (Methylprednisolone or betamethasaone) – Multiple Injections Offered if deterioration of pain relief was <50% Lidocaine 0.5% Only - Multiple Injections Offered if deterioration of pain relief was <50%	≥50 pain relief and functional status improvement
Corticosteroid Injections	Manchikanti 2014	120	405 weeks	43	104 weeks	Injection of local anesthetic and Corticosteroid (betamethasone) – Around 6 procedures in 104 weeks Injection of local anesthetic only – Around 6 procedures in 104 weeks	≥50% reduction in pain and Oswestry disability index
Corticosteroid Injections	Ng 2005	86	58 weeks	51	12 weeks	Single Injection Corticosteroid (Methylprednisolone) and Bupivacaine Single Injection Bupivacaine	At least a 10% reduction in Oswestry Disability Index

Corticosteroid Injections	Nguyen 2017	135	330 weeks	47	4 weeks	Single Injection Contrast and Corticosteroid (Prednisolone) Single Injection Contrast Dye Only	Low back pain intensity <40 on 11 Numerical Rating Scale (0-100 in 10point increments)
Corticosteroid Injections	Saqib 2016	109	60 weeks	NR	4 weeks	Single Injection Corticosteroid (Methylprednisolone) and Bupivacaine Single Injection Bupivacaine	Achieved a moderate disability score (Oswestry Disability Index of 21-40%)
Exercise	Albaladejo 2010	348	Not Reported	52	12 weeks	Four, 1-hour group exercise sessions with physical therapist + Back Book Back Book + 15-minute group talk	Evolution of low back pain: Disappeared or Improved
Exercise	Brandt 2015	13	208 weeks	30	12 weeks	Physical Therapy-delivered core strengthening for 4 days/week Usual activity	MCID in numerical pain scale (Change of 2 or more)
Exercise	Brodsky 2019	69	Not reported	49	12 weeks	Group stretching program, once weekly for 15-30 minutes Self-care book with weekly emails for follow-up	At least 50% reduction in Roland Morris Disability Questionnaire
Exercise	Chan 2017	96	14 weeks	42	10 weeks	Physiotherapy-delivered individualized functional restoration, one weekly for 30 minutes Physiotherapy advice delivered in two, 30- minute sessions	Reduced pain at least 50% on numerical pain scale
Exercise	Costa 2009	154	332 weeks	54	52 weeks	Physiotherapy-delivered motor control exercises, 12, 30-minute sessions Detuned shortwave diathermy and ultrasound delivered over 12, 30-minute sessions	Pain Free (Recovered)
Exercise	Cox 2010	20	588 weeks	45	12 weeks	Yoga classes delivered once weekly for 75 minutes + Back Book + Usual Care Back Book + Usual Care	Roland Disability Questionnaire: At least 2 point improvement
Exercise	Ford 2016	300	15 weeks	44	10 weeks	Individualized physiotherapy delivered once weekly for 30 minute sessions + Advice Advice delivered in two, 30 minute sessions	Reduced pain by <u>></u> 50% on numerical pain scale

Exercise	Frost 2004	286	Not Reported	41	8 weeks	Physiotherapy-delivered exercise; patients received a median of 5 sessions (range 1- 12) averaging 30 minutes in length Advice to stay active delivered in one, 30- minute session	Patient perceived benefit (benefit versus no benefit)
Exercise	Groessl 2017	150	780 weeks	53	12 weeks	Yoga delivered twice a week for 60- minutes a session + Usual Care Delayed Yoga + Usual Care	30% decrease in Roland Morris Disability Questionnaire
Exercise	Hall 2011	160	Not reported	44	10 weeks	Tai Chi; 18, 40-minute sessions + Usual Care Waitlist + Usual Care	At least 30% improvement in pain
Exercise	Hartvigsen 2010	136	Not reported	47	10 weeks	Supervised Nordic Walking; 16, 45-minute sessions Unsupervised Nordic Walking Advice Only	Proportion of patients achieving an MCID on low back pain rating scale (LBPRS)
Exercise	Highland 2018	68	Not reported	44	8 weeks	Therapeutic Yoga; 12, 60-minute sessions Treatment as usual	Proportion of patients reporting MCID (2 point on 11-point scale or 30% reduction)
Exercise	Jensen 2012	100	Not reported	46	10 weeks	Physiotherapy-delivered group exercise; once weekly for 10, 60-minute sessions Rest (avoid physical activity and to rest twice daily for one hour)	Achieved a MCID in pain
Exercise	Moffett 1999	187	Not reported	42	6 weeks	Physiotherapy-delivered exercise; 8, 60- minute sessions Usual Care	Minimum 3 point improvement on Roland Morris Disability Questionnaire
Exercise	Natour 2015	60	Not reported	48	12 weeks	Pilates; 24, 50-minute sessions, delivered twice weekly Waitlist	PGIC rated "much better"
Exercise	Saper 2009	29	Not reported	44	12 weeks	Yoga; once weekly for 75 minutes + Routine Care + Education Book Routine Care + Education Book	Proportion of patients with MCID in pain (≥ 2 point decrease in pain and \geq)
Exercise	Saper 2017	320	Not reported	46	12 weeks	Yoga; once weekly for 75 minutes	At least 30% reduction in back pain

						Physical Therapist-led aerobic exercise; 15, 60-minute sessions Back Pain Help Book	
Exercise	Sherman 2005	101	Not reported	44	12 weeks	Yoga; once weekly for 75 minutes Physical Therapist-led aerobic and strength exercise; once weekly for 75 minutes Back Pain Help Book	At least 50% reduction in Roland Morris Disability Questionnaire
Exercise	Sherman 2011	228	558 weeks	48	12 weeks	Yoga; once weekly for 75 minutes Physiotherapy-led aerobic and stretching exercise; once weekly for 75 minutes Back Pain Help Book	PGIC rated "better", "much better", or "completely gone"
Opioids	Buynak 2010	965	Not reported	50	12 weeks	Oxycodone CR 20-50mg BID Tapentadol ER 100-250mg BID Placebo	≥30% pain relief
Opioids	Cristoph 2017	637	562 weeks	58	12 weeks	Tapentadol PR 200mg BID Cebranopadol 200-600mg QD Placebo	≥30% pain relief
Opioids	Lee 2013	245	Not reported	60	4 weeks	Tramadol/Acetaminopen ER 37.5/325mg 1-2tabs BID Placebo	≥30% pain relief
Opioids	Uberall 2012	236	296 weeks	58	4 weeks	Tramadol ER 200mg QD Placebo	≥30% pain relief
Opioids	Peloso 2004	336	Not reported	58	12 weeks	Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Placebo	≥30% pain relief
Opioids	Ruoff 2003	318	Not reported	54	12 weeks	Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo	≥30% pain relief
Oral NSAIDs	Coats 2004	293	585 weeks	49	4 weeks	Valdecoxib 40 mg daily Placebo	50% reduction in pain

Oral NSAIDs	Katz 2011	129	621 weeks	52	12 weeks	Naproxen 1000 mg daily + Single IV infusion of tanezumab placebo Oral placebo + Single IV infusion of tanezumab placebo	30% reduction in low back pain
Oral NSAIDs	Katz 2003	690	629 weeks	53	4 weeks	Rofecoxib 25 mg daily Rofecoxib 50 mg daily Placebo	PGIC rated- "good" or "excellent"
Oral NSAIDs	Katz 2004 (second publication to Katz 2003)	""	am	""	""		Change in VAS only
Oral NSAIDs	Kivitz 2013	525	585 weeks	52	16 weeks	Naproxen 500 mg twice daily Placebo	30% reduction in pain
Rubefacients	Chrubasik 2010	142	Not reported	48	3 weeks	Capsaicin 0.05% Cream Placebo Cream	≥30% improvement
Rubefacients	Frerick 2003	319	Not reported	NR	3 weeks	Capsaicin Plaster applied once daily for 4- 8 hours Placebo Plaster	≥30% improvement
Rubefacients	Keitel 2001	150	Not reported	NR	3 weeks	Capsaicin Plaster 11 mg applied once daily for 4-12 hours Placebo Plaster	≥30% improvement
SNRI (Duloxetine)	Konno 2016	458	520 weeks	59	12 weeks	Duloxetine 60mg/day Placebo	≥30% reduction in pain
SNRI (Duloxetine)	Skljarevski 2009	404	608 weeks	54	13 weeks	Duloxetine 20, 60 or 120mg/day Placebo	≥30% reduction in pain
SNRI (Duloxetine)	Skljarevski 2010	401	442 weeks	54	12 weeks	Duloxetine 60mg/day Placebo	≥30% reduction in pain
SNRI (Duloxetine)	Skljarevski 2010a	236	476 weeks	52	13 weeks	Duloxetine 60-120mg/day Placebo	>30% reduction brief pain index average pain from baseline

Spinal Manipulation	Bialosky 2014	55	18 weeks	33	2 weeks	Spinal Manipulation; 6 sessions Sham Manipulation; 6 sessions	PGIC rated "good" or "excellent"
Spinal Manipulation	Bond 2020	29	176 weeks	24	3 weeks	Spinal Manipulation; 7 sessions Sham Manipulation; 7 sessions	Proportion of patients who met MCID (reduction of \geq 1.25 on 11-point VAS pain scale)
Spinal Manipulation	Ford 2019	64	16 weeks	45	10 weeks	Spinal Manipulation; 10, 30-minute sessions Guidance-based Advice; 2, 30-minute sessions	50% or greater reduction in pain
Spinal Manipulation	Goertz 2017	83	Not reported	73	12 weeks	Spinal Manipulation (median 17.5 visits) + Medical Care Medical Care; median 2 visits	PGIC rated "completely gone", "much better" or "moderately better"
Spinal Manipulation	Licciardone 2013	455	Not reported	41	12 weeks	Spinal Manipulation; 6, 15-minute sessions Sham Manipulation; 6, 15-minute sessions	30% or greater reduction in pain
Topical NSAIDs	Song 2008	127	Not Reported	52	1 week	Flurbiprofen Tape 63 mg/day worn 12 or 24 hours Placebo Tape, worn 12 or 24 hours	PGIC rated "very much improved, much improved or improved"

Table 3: Overall proportion of patients with meaningful response and proportion at less than or equal to four weeks, four to twelve weeks and at greater than twelve weeks.

Intervention Type	Number of RCTs	Subgroup	Intervention Event Rate	Control Event Rate	Risk Ratio (95% Cl)	NNT
	18	Overall Efficacy	50% (734/1472)	35% (386/1089)	RR 1.71 (95% Cl 1.37, 2.15)	7
Exercise	1	Assessed at: <u><</u> 4 weeks	40% (4/10)	30% (3/10)	RR 1.33 (95% Cl 0.40, 4.49)	NSS
	11	Assessed at: >4 weeks to <12 weeks	47% (446/939)	27% (210/790)	RR 2.04 (95% Cl 1.66, 2.51)	5
	10	Assessed at: <a>>12 weeks	49% (383/779)	44% (199/449)	RR 1.64 (95% Cl 1.16, 2.32)	21
	8	Overall Efficacy	54% (1320/2457)	35% (754/2161)	RR 1.58 (95% Cl 1.13, 2.21)	6
Acupuncture	1	Assessed at: <u><</u> 4 weeks	60% (39/65)	33% (20/61)	RR 1.83 (95% Cl 1.21, 2.76)	4
	6	Assessed at: >4 weeks to <12 weeks	53% (501/941)	50% (352/710)	RR 1.26 (0.99, 1.62)	NSS
	2	Assessed at: <a>>12 weeks	55% (1015/1838)	34% (611/1777)	RR 1.49 (95% Cl 0.75, 2.98)	NSS
	10	Overall Efficacy	48% (276/581)	45% (257/571)	RR 1.07 (95% CI 0.87, 1.30)	NSS
Corticosteroid	5	Assessed at: <u><</u> 4 weeks	30% (99/333)	22% (70/324)	RR 1.55 (95% Cl 0.93, 2.59)	NSS
Injections	-	Assessed at: >4 weeks to <12 weeks	-	-	-	-
	7	Assessed at: <a>>12 weeks	50% (221/446)	50% (217/435)	RR 1.01 (95% CI 0.82, 1.24)	NSS

Interventions are Ordered by Highest to Lowest Risk Ratio of Overall Efficacy.

RCTs: Randomized Controlled Trials; RR: Risk Ratio; Cl: Confidence Interval; RR: Risk Ratio; NNT: Number Needed to Treat; NSS: Not statistically significant

Table 4: Overall proportion of patients with meaningful response at longest follow-up point after interventionInterventions ordered by Highest to Lowest Risk Ratio (RR)

Intervention Type	Number of RCTs	Follow-up (range in weeks)	Intervention Event Rate	Control Event Rate	Risk Ratio (95% Cl)	NNT
Exercise	11	12-48 Weeks After Intervention	53% (526/987)	37% (322/881)	RR 1.58 (95% Cl 1.32, 1.89)	6
Acupuncture	4	8-45 Weeks After Intervention	49% (213/437)	40% (111/277)	RR 1.42 (0.87, 2.32)	NSS
Spinal Manipulation	1	42 Weeks After Intervention	61% (20/33)	45% (14/31)	RR 1.34 (0.83, 2.16)	NSS

RCTs: Randomized Controlled Trials; RR: Risk Ratio; Cl: Confidence Interval; RR: Risk Ratio; NNT: Number Needed to Treat; NSS: Not statistically significant

Table 5: Proportion of patients with clinically meaningful response based on funding source (clearly publicly or industry funding)Interventions ordered by Highest to Lowest Risk Ratio (RR)

Intervention Type	Number of RCTs	Subgroup	Intervention Event Rate	Control Event Rate	Risk Ratio (95% Cl)	NNT	p-value Between Subgroups
Exercise	17	Public Funding	52% (714/1381)	36% (378/1044)	RR 1.76 (95% Cl 1.38, 2.23)	7	NA
LAEICISE	0	Industry Funding	-	-	-	-	
Acupuncturo	7	Public Funding	54% (1302/2417)	35% (745/2121)	RR 1.54 (95% Cl 1.08, 2.20)	6	NA
Acupuncture	0	Industry Funding	-	-	-	-	NA
Corticosteroid	7	Public Funding	44% (212/478)	44% (205/469)	RR 1.01 (95% CI 0.82, 1.24)	-	NA
Injections	0	Industry Funding	-	-	-	-	

RCTs: Randomized Controlled Trials; RR: Risk Ratio; Cl: Confidence Interval; RR: Risk Ratio; NNT: Number Needed to Treat; NA: Not Applicable

Table 6: Proportion of patients with clinically meaningful response based on median risk of bias scores

Intervention Type	Number of RCTs	Subgroup	Intervention Event Rate	Control Event Rate	Risk Ratio (95% Cl)	NNT	p-value
	7	Less than the median risk of bias score	57% (326/569)	42% (253/596)	RR 1.55 (95% Cl 1.03, 2.32)	7	
Exercise	11	Greater than or equal to the median risk of bias score	45% (408/903)	27% (133/493)	RR 1.71 (95% Cl 1.42, 2.05)	6	P=0.66
	4	Less than the median risk of bias score	63% (511/807)	59% (386/650)	RR 1.22 (95% Cl 0.97, 1.55)	NSS	
Acupuncture	4	Greater than or equal to the median risk of bias score	49% (809/1650)	24% (368/1511)	RR 1.89 (95% Cl 1.42, 2.51)	5	P=0.02
Corticosteroid	5	Less than the median risk of bias score	56% 113/202	51% 102/200	RR 1.11 (95% CI 0.78, 1.59)	NSS	
Injections	5	Greater than or equal to the median risk of bias score	43% 163/379	42% 155/371	RR 1.03 (95% CI 0.81, 1.32)	NSS	P=0.73

Ordered by Highest to Lowest Risk Ratio (RR).

RCTs: Randomized Controlled Trials; NNT: Number Needed to Treat; NSS: Not Statistically Significant; CI: Confidence Interval; RR: Risk Ratio

Data Analysis

Exercise

Figure 1.1: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment.

	Exerc	ise	No Exe	rcise		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Albaledejo 2010	77	100	115	139	8.0%	0.93 [0.82, 1.06]	-
Brandt 2015	3	5	1	7	1.2%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	5.9%	1.09 [0.67, 1.79]	- -
Chan 2017	27	50	13	46	5.7%	1.91 [1.13, 3.24]	
Cox 2010	4	10	5	10	3.2%	0.80 [0.30, 2.13]	
Ford 2016	99	156	49	144	7.5%	1.86 [1.44, 2.41]	-
Frost 2004	93	144	64	142	7.7%	1.43 [1.15, 1.78]	-
Groessl 2017	33	75	25	75	6.5%	1.32 [0.88, 1.99]	+ - -
Hall 2011	37	80	12	80	5.4%	3.08 [1.74, 5.47]	
Hartvigsen 2010a	10	45	4	23	3.0%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	3.0%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	4.5%	2.71 [1.32, 5.60]	
Jensen 2012	9	49	4	51	2.8%	2.34 [0.77, 7.11]	+
Moffett 1999	47	89	30	98	6.9%	1.73 [1.21, 2.47]	
Natour 2015	7	30	4	30	2.7%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	2.1%	4.67 [1.23, 17.68]	
Saper 2017a	44	127	7	32	4.6%	1.58 [0.79, 3.18]	+
Saper 2017b	48	129	8	32	5.0%	1.49 [0.78, 2.82]	+
Sherman 2005a	25	36	4	15	3.7%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	4.1%	1.54 [0.70, 3.38]	
Sherman 2011a	55	92	4	22	3.6%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	2.9%	3.54 [1.20, 10.40]	· · · · ·
Total (95% CI)		1472		1089	100.0%	1.71 [1.37, 2.15]	•
Total events	734		386				
Heterogeneity: Tau ² =	= 0.16; Cl	ni² = 8	5.66, df =	= 21 (P	< 0.0000	1); $I^2 = 75\%$	0.01 0.1 1 10 100
Test for overall effect							0.01 0.1 1 10 100 Favours no exercise Favours exercise
			-,				ravours no exercise ravours exercise

Figure 1.2: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less.

	Exerc	ise	No Exe	rcise		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Cox 2010	4	10	3	10	100.0%	1.33 [0.40, 4.49]	
Total (95% CI)		10		10	100.0%	1.33 [0.40, 4.49]	
Total events	4		3				
Heterogeneity: Not ap Test for overall effect	•	6 (P = 0).64)				0.01 0.1 1 10 100 Favours no exercise Favours exercise


Figure 1.3: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks.

	Exerc	ise	No Exe	cise		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Chan 2017	27	50	13	46	9.2%	1.91 [1.13, 3.24]	_ _ _
Ford 2016	99	156	49	144	17.2%	1.86 [1.44, 2.41]	-
Frost 2004	93	144	64	142	18.5%	1.43 [1.15, 1.78]	-
Groessl 2017	25	33	16	75	10.4%	3.55 [2.21, 5.71]	
Hall 2011	37	80	12	80	8.3%	3.08 [1.74, 5.47]	
Hartvigsen 2010a	10	45	4	23	3.3%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	3.3%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	6.0%	2.71 [1.32, 5.60]	
Jensen 2012	9	49	4	51	3.0%	2.34 [0.77, 7.11]	
Moffett 1999	47	89	30	98	13.7%	1.73 [1.21, 2.47]	
Natour 2015	7	30	2	30	1.8%	3.50 [0.79, 15.49]	
Sherman 2011a	32	92	3	22	3.1%	2.55 [0.86, 7.57]	+
Sherman 2011b	31	91	2	23	2.1%	3.92 [1.01, 15.18]	
Total (95% CI)		939		790	100.0%	2.04 [1.66, 2.51]	•
Total events	446		210				
Heterogeneity: Tau ² =	= 0.05; Cł	1i ² = 20	0.81, df =	12 (P	= 0.05); I	² = 42%	0.01 0.1 1 10 10
Test for overall effect	: Z = 6.80) (P < 0).00001)				Favours no exercise Favours exercise

Figure 1.4: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater.

	Exerc	ise	No Exe	rcise		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Albaledejo 2010	77	100	115	139	13.1%	0.93 [0.82, 1.06]	-
Brandt 2015	3	5	1	7	2.6%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	10.5%	1.09 [0.67, 1.79]	_ _
Cox 2010	4	10	5	10	6.5%	0.80 [0.30, 2.13]	
Groessl 2017	33	75	25	75	11.2%	1.32 [0.88, 1.99]	+
Natour 2015	7	30	4	30	5.6%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	4.5%	4.67 [1.23, 17.68]	· · · · · · · · · · · · · · · · · · ·
Saper 2017a	44	127	7	32	8.7%	1.58 [0.79, 3.18]	+
Saper 2017b	48	129	8	32	9.2%	1.49 [0.78, 2.82]	+
Sherman 2005a	25	36	4	15	7.3%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	7.9%	1.54 [0.70, 3.38]	—
Sherman 2011a	55	92	4	22	7.0%	3.29 [1.33, 8.10]	_
Sherman 2011b	42	91	3	23	5.9%	3.54 [1.20, 10.40]	
Total (95% CI)		779		449	100.0%	1.64 [1.16, 2.32]	◆
Total events	383		199				
Heterogeneity: $Tau^2 =$	0.24; Cł	ni ² = 46	5.23, df =	= 12 (P	< 0.0000	1); $ ^2 = 74\%$	
Test for overall effect						• •	0.01 0.1 1 10 10 Favours no exercise Favours exercise

Figures 1.5: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response at longest follow up time.



Figures 1.6: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding)

	Exerci		No Exer			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
1.8.1 Public Funding							
Albaledejo 2010	77	100	115	139	8.4%	0.93 [0.82, 1.06]	
Brandt 2015	3	5	1	7	1.3%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	6.3%	1.09 [0.67, 1.79]	
Chan 2017	27	50	13	46	6.1%	1.91 [1.13, 3.24]	
Cox 2010	4	10	5	10	3.5%	0.80 [0.30, 2.13]	
Ford 2016	99	156	49	144	7.8%	1.86 [1.44, 2.41]	-
Frost 2004	93	144	64	142	8.0%	1.43 [1.15, 1.78]	-
Groessl 2017	33	75	25	75	6.9%	1.32 [0.88, 1.99]	+
Hall 2011	37	80	12	80	5.7%	3.08 [1.74, 5.47]	
Highland 2018	19	34	7	34	4.8%	2.71 [1.32, 5.60]	
Jensen 2012	9	49	4	51	3.0%	2.34 [0.77, 7.11]	
Moffett 1999	47	89	30	98	7.2%	1.73 [1.21, 2.47]	
Natour 2015	7	30	4	30	3.0%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	2.3%	4.67 [1.23, 17.68]	
Saper 2017a	44	127	7	32	5.0%	1.58 [0.79, 3.18]	
Saper 2017b	48	129	8	32	5.3%	1.49 [0.78, 2.82]	
Sherman 2005a	25	36	4	15	4.0%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	4.5%	1.54 [0.70, 3.38]	
Sherman 2011a	55	92	4	22	3.9%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	3.1%	3.54 [1.20, 10.40]	
Subtotal (95% CI)		1381		1044	100.0%	1.76 [1.38, 2.23]	•
Total events	714		378				
Heterogeneity: Tau ² = 0	.17: Chi ²	= 86.3	7. df = 19	(P < 0.0)	00001): l ² :	= 78%	
Test for overall effect: Z				(,, .		
1.8.2 Industry Funding	1						
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not appl							
Test for overall effect: N	lot applic	able					
Fotal (95% CI)		1381		1044	100.0%	1.76 [1.38, 2.23]	•
Total events	714		378				
Heterogeneity: Tau ² = 0		= 86.3		(P < 0.0)	00001): I ² :	= 78%	
Test for overall effect: Z	,		,		,,.		0.01 0.1 1 10 1
Test for subgroup difference			,				Favours no exercise Favours exercise

Figures 1.7: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score)

For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)

Study or SubgroupEv1.7.1 Less than the medAlbaledejo 2010Cox 2010Ford 2016Frost 2004Hall 2011Jensen 2012Natour 2015Subtotal (055% Cl)Total eventsHeterogeneity: Tau ² = 0.	dian risk 77 4 99 93 37 9 7 326 .20; Chi ²	<pre>< of b 100 10 156 144 80 49 30 569 </pre>	ias score 115 5 49 64 12 4 4 4 253 2.66, df =	139 10 144 142 80 51 30 596	8.0% 3.2% 7.5% 7.7% 5.4% 2.8% 2.7% 37.3%	M-H, Random, 95% CI 0.93 [0.82, 1.06] 0.80 [0.30, 2.13] 1.86 [1.44, 2.41] 1.43 [1.15, 1.78] 3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	М-H, Random, 95% СІ
Albaledejo 2010 Cox 2010 Ford 2016 Frost 2004 Hall 2011 Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	77 4 99 93 37 9 7 326 .20; Chi ²	$100 \\ 10 \\ 156 \\ 144 \\ 80 \\ 49 \\ 30 \\ 569 \\ ^{2} = 52$	115 5 49 64 12 4 4 253 2.66, df =	139 10 144 142 80 51 30 596	3.2% 7.5% 7.7% 5.4% 2.8% 2.7% 37.3%	0.80 [0.30, 2.13] 1.86 [1.44, 2.41] 1.43 [1.15, 1.78] 3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	• • • • • •
Cox 2010 Ford 2016 Frost 2004 Hall 2011 Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	4 99 93 37 9 7 326 .20; Chi ²	$ \begin{array}{r} 10 \\ 156 \\ 144 \\ 80 \\ 49 \\ 30 \\ 569 \\ ^{2} = 52 \\ \end{array} $	5 49 64 12 4 4 253 2.66, df =	10 144 142 80 51 30 596	3.2% 7.5% 7.7% 5.4% 2.8% 2.7% 37.3%	0.80 [0.30, 2.13] 1.86 [1.44, 2.41] 1.43 [1.15, 1.78] 3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	
Ford 2016 Frost 2004 Hall 2011 Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	99 93 37 9 7 326 .20; Chi ²	$156 \\ 144 \\ 80 \\ 49 \\ 30 \\ 569 \\ 2^{2} = 52$	49 64 12 4 4 253 2.66, df =	144 142 80 51 30 596	7.5% 7.7% 5.4% 2.8% 2.7% 37.3%	1.86 [1.44, 2.41] 1.43 [1.15, 1.78] 3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	
Frost 2004 Hall 2011 Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	93 37 9 7 326 .20; Chi ²	$ \begin{array}{r} 144 \\ 80 \\ 49 \\ 30 \\ 569 \\ ^{2} = 52 \end{array} $	64 12 4 4 253 2.66, df =	142 80 51 30 596	7.7% 5.4% 2.8% 2.7% 37.3%	1.43 [1.15, 1.78] 3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	
Hall 2011 Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	37 9 7 326 .20; Chi ²	80 49 30 569 ² = 52	12 4 4 253 2.66, df =	80 51 30 596	5.4% 2.8% 2.7% 37.3%	3.08 [1.74, 5.47] 2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	
Jensen 2012 Natour 2015 Subtotal (95% CI) Total events	9 7 326 .20; Chi ²	49 30 569 ² = 52	4 4 253 2.66, df =	51 30 596	2.8% 2.7% 37.3%	2.34 [0.77, 7.11] 1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	 →
Natour 2015 Subtotal (95% CI) Total events	7 326 .20; Chi ²	30 569 ² = 52	4 253 2.66, df =	30 596	2.7% 37.3%	1.75 [0.57, 5.36] 1.55 [1.03, 2.32]	 ◆
Subtotal (95% CI) Total events	326 .20; Chi²	569	253 2.66, df =	596	37.3%	1.55 [1.03, 2.32]	•
Total events	.20; Chi ²	² = 52	2.66, df =				•
	.20; Chi ²		2.66, df =	6 (P <	0 00001		
Heterogeneity: $Tau^2 = 0.1$				6 (P <	0 00001	2	
	= 2.11 ((P = 0)	0.00	50 1	0.00001); I ² = 89%	
Test for overall effect: Z			1.03)				
1.7.2 Greater than or eq	qual to t	the m	edian ris	sk of bi	as score		
Brandt 2015	3	5	1	7	1.2%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	5.9%	1.09 [0.67, 1.79]	- -
Chan 2017	27	50	13	46	5.7%	1.91 [1.13, 3.24]	
Groessl 2017	33	75	25	75	6.5%	1.32 [0.88, 1.99]	+ - -
Hartvigsen 2010a	10	45	4	23	3.0%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	3.0%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	4.5%	2.71 [1.32, 5.60]	
Moffett 1999	47	89	30	98	6.9%	1.73 [1.21, 2.47]	
Saper 2009	10	15	2	14	2.1%	4.67 [1.23, 17.68]	
Saper 2017a	44	127	7	32	4.6%	1.58 [0.79, 3.18]	+
Saper 2017b	48	129	8	32	5.0%	1.49 [0.78, 2.82]	+
Sherman 2005a	25	36	4	15	3.7%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	4.1%	1.54 [0.70, 3.38]	
Sherman 2011a	55	92	4	22	3.6%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	2.9%	3.54 [1.20, 10.40]	
Subtotal (95% CI)		903		493	62.7%	1.71 [1.42, 2.05]	◆
Total events	408		133				
Heterogeneity: $Tau^2 = 0.0$: 14 (P :	= 0.34); I	$^{2} = 10\%$	
Test for overall effect: Z	= 5.72 ((P < 0	.00001)				
Total (95% CI)	1	472		1089	100.0%	1.71 [1.37, 2.15]	◆
Total events	734		386				
Heterogeneity: $Tau^2 = 0$.	.16; Chi ²	2 = 85	5.66, df =	21 (P ·	< 0.0000	1); $I^2 = 75\%$	0.01 0.1 1 10 100
Test for overall effect: Z =							0.01 0.1 1 10 100 Favours no exercise Favours exercise
Test for subgroup differe	ences: C	hi² =	0.19, df	= 1 (P =	= 0.66), I ³	$^{2} = 0\%$	ravours no exercise ravours exercise

Acupuncture

Figure 2.1: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment.

	Acupun	cture	Conti	rol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% Cl
Brinkhaus 2006	76	146	27	73	14.6%	1.41 [1.00, 1.97]		
Cherkin 2009	150	315	80	162	16.2%	0.96 [0.79, 1.17]		+
Coan 1980	15	25	6	25	9.0%	2.50 [1.16, 5.39]		— -
Haake 2007	304	387	277	387	17.0%	1.10 [1.01, 1.19]		-
Meng 2003	7	28	1	23	2.4%	5.75 [0.76, 43.41]		· · · · · · · · · · · · · · · · · · ·
Molsberger 1998	39	65	20	61	13.7%	1.83 [1.21, 2.76]		
Qin 2019	18	40	9	40	10.2%	2.00 [1.02, 3.91]		
Witt 2006	711	1451	334	1390	16.9%	2.04 [1.83, 2.27]		•
Total (95% CI)		2457		2161	100.0%	1.58 [1.13, 2.21]		◆
Total events	1320		754					
Heterogeneity: Tau ² =	= 0.17; Ch	$i^2 = 120$).27, df =	= 7 (P <	< 0.0000	1); $I^2 = 94\%$		
Test for overall effect	: Z = 2.68	B (P = 0.	007)				0.01	0.1 1 10 100 Favours control Favours acupuncture

Figure 2.2: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less.

	Acupun					Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		М-Н,	Random, 95%	CI		
Molsberger 1998	39	65	20	61	100.0%	1.83 [1.21, 2.76]						
Total (95% CI)		65		61	100.0%	1.83 [1.21, 2.76]			•			
Total events	39		20									
Heterogeneity: Not ap	oplicable						0.01	01	1	10	100	
Fest for overall effect: $Z = 2.89$ (P = 0.004)							0.01	Favours co	ontrol Favours			

Figure 2.3: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks.

	Acupun	cture	Conti	rol		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% Cl
Brinkhaus 2006	76	146	27	73	20.8%	1.41 [1.00, 1.97]		- - -
Cherkin 2009	150	315	80	162	28.2%	0.96 [0.79, 1.17]		+
Coan 1980	15	25	6	25	7.9%	2.50 [1.16, 5.39]		
Haake 2007	235	387	229	387	31.9%	1.03 [0.91, 1.15]		•
Meng 2003	7	28	1	23	1.4%	5.75 [0.76, 43.41]		· · · · · · · · · · · · · · · · · · ·
Qin 2019	18	40	9	40	9.7%	2.00 [1.02, 3.91]		
Total (95% CI)		941		710	100.0%	1.26 [0.99, 1.62]		◆
Total events	501		352					
Heterogeneity: Tau ² =	= 0.05; Ch	$i^2 = 15$.	33, df =	5 (P =	0.009); I ²	= 67%		
Test for overall effect	:: Z = 1.86	(P=0.	06)				0.01	0.1 1 10 100 Favours control Favours acupuncture

Figure 2.4: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater.

	Acupuncture Acupuncture		Cont	rol		Risk Ratio	Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		М-Н,	Random, 95%	6 CI	
Haake 2007	304	387	277	387	50.1%	1.10 [1.01, 1.19]			•		
Witt 2006	711	1451	334	1390	49.9%	2.04 [1.83, 2.27]					
Total (95% CI)		1838		1777	100.0%	1.49 [0.75, 2.98]					
Total events	1015		611								
Heterogeneity: Tau ² =				= 1 (P <	0.00001	L); $I^2 = 99\%$	0.01	0.1	1	10	100
rest for overall effect	or overall effect: $Z = 1.14$ (P = 0.25)					Favours co	ontrol Favour:	s acupunct [,]	ure		

Figure 2.5: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response at longest follow up time


	Acupun	cture	Conti	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl	
Cherkin 2009	145	315	76	162	31.0%	0.98 [0.80, 1.20]	+	
Hunter 2011	11	27	10	24	20.7%	0.98 [0.51, 1.89]	_	
Kerr 2003	21	30	13	30	25.2%	1.62 [1.01, 2.59]	- - -	
Molsberger 1998	36	65	12	61	23.2%	2.82 [1.62, 4.89]	│ — -	
Total (95% CI)		437		277	100.0%	1.42 [0.87, 2.32]	•	
Total events	213		111					
Heterogeneity: Tau ²	= 0.19; Ch	$i^2 = 14.$	92, df =	3 (P =	0.002); I ²	= 80%		100
Test for overall effect	z = 1.40	(P=0.	16)				0.01 0.1 1 10 Favours [experimental] Favours [control]	100

Figure 2.6: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding)

	Acupun	cture	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
1.7.1 Public Funding							
Brinkhaus 2006	76	146	27	73	16.3%	1.41 [1.00, 1.97]	
Cherkin 2009	150	315	80	162	18.1%	0.96 [0.79, 1.17]	+
Coan 1980	15	25	6	25	10.1%	2.50 [1.16, 5.39]	_ - -
Haake 2007	304	387	277	387	18.9%	1.10 [1.01, 1.19]	•
Meng 2003	7	28	1	23	2.7%	5.75 [0.76, 43.41]	+
Molsberger 1998	39	65	20	61	15.2%	1.83 [1.21, 2.76]	
Witt 2006 Subtotal (95% CI)	711	1451 2417	334	1390 2121	18.8% 100.0%	2.04 [1.83, 2.27] 1.54 [1.08, 2.20]	
Heterogeneity: Tau ² = (Test for overall effect: 2 1.7.2 Industry Funding Subtotal (95% CI)	z = 2.38 (F			P < 0.0 0	0001); l² =	95% Not estimable	
Total events Heterogeneity: Not app Test for overall effect: N		-	0	U		Not estimable	
Total (95% CI)		2417		2121	100.0%	1.54 [1.08, 2.20]	◆
Total events	1302		745				
Heterogeneity: Tau ² = 0 Test for overall effect: 2 Test for subgroup differ	z = 2.38 (F	P = 0.02)		P < 0.0	0001); l² =	- 95%	0.01 0.1 1 10 100 Favours control Favours acupuncture

Figure 2.7: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score)

For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)



Spinal Manipulation

Figure 3.1: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment

	Spinal Manipu	lation	Contr	ol		Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Ra	andom, 95%	CI	
Bialosky 2014	7	28	6	27	9.4%	1.13 [0.43, 2.92]		-			
Bond 2020	6	14	7	15	12.1%	0.92 [0.41, 2.07]		_	— • —		
Ford 2019	28	33	11	31	23.4%	2.39 [1.46, 3.93]					
Goertz 2017	13	44	5	39	9.6%	2.30 [0.90, 5.88]				_	
Licciardone 2013	145	230	103	225	45.5%	1.38 [1.16, 1.64]			-		
Total (95% CI)		349		337	100.0%	1.54 [1.11, 2.12]			•		
Total events	199		132								
Heterogeneity: Tau ² =	= 0.05; Chi ² = 6.	70, df =	4 (P = 0.	15); I ²	= 40%			- 1		10	100
Test for overall effect							0.01	0.1 Favours con	trol Favours	10 manipulat	100 tion

Figure 3.2: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less. (Post hoc analysis)




Figure 3.3: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks. (Post hoc analysis)

	Spinal Manipulati					Risk Ratio		Risk Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI			
Ford 2019	28	33	11	31	100.0%	2.39 [1.46, 3.93]					
Total (95% CI)		33		31	100.0%	2.39 [1.46, 3.93]			•		
Total events	28		11								
Heterogeneity: Not a Test for overall effect		.0006)					0.01	0.1 Favours c	1 ontrol Favours	10 s manipula	100 tion

Figure 3.4: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater. (Post hoc analysis)

	Spinal Manipu	lation	Conti	ol		Risk Ratio		R	Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, R	andom, 95% (CI	
Goertz 2017	44	5	39	9.5%	2.30 [0.90, 5.88]				-		
Licciardone 2013	145	230	103	225	90.5%	1.38 [1.16, 1.64]					
Total (95% CI)		274		264	100.0%	1.45 [1.07, 1.95]			•		
Total events	158		108								
			1 (P = 0)	28); I ²	= 13%		0.01	0.1	1	10	100
Test for overall effect	eity: Tau ² = 0.02; Chi ² = 1.15, df = 1 (P = 0.28); I ² = 13; verall effect: Z = 2.42 (P = 0.02)							*	Itrol Favours	manipulat	


Figure 3.5: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response at longest follow up time.

	Spinal Manipu	ulation	Control			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Ford 2019	20	33	14	31	100.0%	1.34 [0.83, 2.16]	-
Total (95% CI)		33		31	100.0%	1.34 [0.83, 2.16]	•
Total events	20		14				
Heterogeneity: Not a	oplicable						0.01 0.1 1 10 100
Test for overall effect: $Z = 1.21$ (P = 0.23)						Favours [experimental] Favours [control]	

Figure 3.6: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

	Spinal Manipu		Contr			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.8.1 Public Funding							
Bialosky 2014	7	28	6	27	9.4%	1.13 [0.43, 2.92]	
Bond 2020	6	14	7	15	12.1%	0.92 [0.41, 2.07]	
Ford 2019	28	33	11	31	23.4%	2.39 [1.46, 3.93]	
Goertz 2017	13	44	5	39	9.6%	2.30 [0.90, 5.88]	
Licciardone 2013 Subtotal (95% CI)	145	230 349	103	225 337	45.5% 100.0%	1.38 [1.16, 1.64] 1.54 [1.11, 2.12]	•
Total events	199		132				
rest for overall effect: 2	2 – 2.02 (P – 0.0	109)					
Test for overall effect: 2 1.8.2 Industry Funding Subtotal (95% CI)	,	09)		0		Not estimable	
1.8.2 Industry Funding Subtotal (95% CI) Total events Heterogeneity: Not app	g 0 blicable	,	0	0		Not estimable	
1.8.2 Industry Funding	g 0 blicable	,	0	-	100.0%	Not estimable 1.54 [1.11, 2.12]	•
1.8.2 Industry Funding Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: N Total (95% CI)	g 0 blicable	0	0	-	100.0%		•
1.8.2 Industry Funding Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: N Total (95% CI) Total events	g 0 vlicable Not applicable 199	0 349	132	337			► 10 10 10
1.8.2 Industry Funding Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: N	g 0 votapplicable 199 0.05; Chi ² = 6.70	0 349), df = 4 (l	132	337			0.01 0.1 1 10 10 Favours control Favours manipulation

Figure 3.7: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) (post hoc analysis) *For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)*



Oral NSAIDs

Figure 4.1: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment.

	NSAII	Ds	Cont	rol		Risk Ratio		Risk F	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rando	om, 95% Cl	
Coats 2004	96	148	77	145	24.1%	1.22 [1.01, 1.48]		-	•	
Katz 2003a	149	233	39	114	20.0%	1.87 [1.42, 2.45]				
Katz 2003b	142	229	39	114	19.9%	1.81 [1.38, 2.38]				
Katz 2011	45	88	20	41	15.3%	1.05 [0.72, 1.52]		-	-	
Kivitz 2013	111	295	62	230	20.7%	1.40 [1.08, 1.81]				
Total (95% CI)		993		644	100.0%	1.44 [1.17, 1.78]			•	
Total events	543		237							
Heterogeneity: Tau ² =	= 0.04; Cł	$ni^2 = 12$	2.16, df :	= 4 (P =	= 0.02); I ²	= 67%		01 1	10	100
Test for overall effect	:: Z = 3.47	7 (P = 0).0005)				0.01	0.1 1 Favours control	. 10 Favours NSAIDs	100

Figure 4.2: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less. (Post hoc analysis)




Figure 4.3: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at greater than 4 weeks and less than 12 weeks. (Post hoc analysis)

	NSAI	Ds	Control			Risk Ratio		Risk Ratio				
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		М-Н,	Random, 95	% CI		
Katz 2011	50	88	13	41	100.0%	1.79 [1.10, 2.91]						
Total (95% CI)		88		41	100.0%	1.79 [1.10, 2.91]			•			
Total events	50		13									
Heterogeneity: Not ap	oplicable						0.01	0.1		10	100	
Test for overall effect	:: Z = 2.3	6 (P = 0).02)				0.01		ontrol Favour			

Figure 4.4: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater. (Post hoc analysis)




Figure 4.5: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

	NSAI	SAIDs Control			Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-	H, Random, 95% Cl	
1.12.1 Public Funding Subtotal (95% CI)	l	0		0		Not estimable			
Total events	0		0						
Heterogeneity: Not app	licable								
Test for overall effect: N	Not applic	able							
1.12.2 Industry Fundir	ng								
Katz 2003a	149	233	39	114	26.4%	1.87 [1.42, 2.45]		-	
Katz 2003b	142	229	39	114	26.2%	1.81 [1.38, 2.38]			
Katz 2011	45	88	20	41	20.1%	1.05 [0.72, 1.52]		-	
Kivitz 2013	111	295	62	230	27.3%	1.40 [1.08, 1.81]		-	
Subtotal (95% CI)		845		499	100.0%	1.52 [1.20, 1.93]		◆	
Total events	447		160						
Heterogeneity: Tau ² = (0.04; Chi ²	= 7.93	, df = 3 (P	9 = 0.05	5); l² = 62%	6			
Test for overall effect: 2	Z = 3.50 (F	P = 0.0	005)						
Total (95% CI)		845		499	100.0%	1.52 [1.20, 1.93]		•	
Total events	447		160						
Heterogeneity: Tau ² = (0.04; Chi ²	= 7.93	, df = 3 (P	9 = 0.05	5); l² = 62%	6			
Test for overall effect: 2							0.01 0.1	1 10	100
Test for subgroup differ							Favours	control Favours NSAIDs	

Figure 4.6: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) (post hoc analysis) *For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)*

	NSAI		Conti			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
1.10.1 Less than the	e median I	risk of	bias sco	ore			
Coats 2004	96	148	77	145	24.1%	1.22 [1.01, 1.48]	
Katz 2003a	149	233	39	114	20.0%	1.87 [1.42, 2.45]	
Katz 2003b Subtotal (95% CI)	142	229 610	39	114 373		1.81 [1.38, 2.38] 1.59 [1.17, 2.15]	
Total events	387		155				
Heterogeneity: Tau ² Test for overall effec	t: Z = 2.98	8 (P = 0).003)	·			
1.10.2 Greater than							
Katz 2011	45	88	20	41			
Kivitz 2013 Subtotal (95% CI)	111	295 383	62	230 271		1.40 [1.08, 1.81] 1.25 [0.95, 1.65]	
Total events	156		82				
Heterogeneity: Tau ² Test for overall effec	,		,	1 (P =	0.21); I ² =	= 36%	
Total (95% CI)		993		644	100.0%	1.44 [1.17, 1.78]	▲
Total events Heterogeneity: Tau ² Test for overall effec Test for subgroup di	t: Z = 3.47	7 (P = 0).0005)	,			0.01 0.1 1 10 100 Favours control Favours NSAIDs

Rubefacients

Figure 5.1: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful response to treatment.

	Rubefac	ients	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Chrubasik 2010	52	71	35	71	28.4%	1.49 [1.13, 1.96]	-
Frerick 2003	98	159	75	160	50.7%	1.31 [1.07, 1.61]	=
Keitel 2001	45	74	32	76	20.8%	1.44 [1.05, 1.99]	
Total (95% CI)		304		307	100.0%	1.39 [1.20, 1.61]	•
Total events	195		142				
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.56, 0	df = 2 (P =				
Test for overall effect:	Z = 4.39 (F	P < 0.000	01)				0.01 0.1 1 10 100 Favours [Placebo] Favours [Rubefacients]

Figure 5.2: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less. (Post hoc analysis)





Figure 5.3: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

	Rubefaci	ents	Placel	00		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rano	dom, 95% C	1	
1.9.1 Public Funding Subtotal (95% Cl)		0		0		Not estimable					
Total events Heterogeneity: Not app	0 Jicable		0								
Test for overall effect: N		ble									
1.9.2 Industry Funding	g										
Chrubasik 2010 Subtotal (95% CI)	52	71 71	35	71 71	100.0% 100.0%	1.49 [1.13, 1.96] 1.49 [1.13, 1.96]			•		
Total events	52		35								
Heterogeneity: Not app Test for overall effect: 2		= 0.005	5)								
Total (95% CI)		71		71	100.0%	1.49 [1.13, 1.96]			•		
Total events Heterogeneity: Not app Test for overall effect: 2 Test for subgroup differ	Z = 2.83 (P		'				0.01	0.1 Favours [Placebo]	1 Favours [F	10 Rubefacier	100 nts]

Figure 5.4: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) (post hoc analysis) For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)



Opioids

Figure 6.1: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response to treatment.

	Opioi	ds	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
1.1.1 Opioid Only							
Buynak 2010 (Oxycodone)	99	328	43	160	12.8%	1.12 [0.83, 1.52]	
Buynak 2010 (Tapentadol)	125	318	43	159	13.1%	1.45 [1.09, 1.94]	
Cristoph 2017 (Cebranopadol)	117	385	23	63	11.5%	0.83 [0.58, 1.19]	- - -
Cristoph 2017 (Tapentadol)	57	126	24	63	11.3%	1.19 [0.82, 1.72]	
Uberall 2012	52	116	57	120	13.4%	0.94 [0.72, 1.24]	-
Subtotal (95% CI)		1273		565	62.2%	1.09 [0.90, 1.32]	◆
Total events	450		190				
Heterogeneity: Tau ² = 0.02; Chi ²	= 7.32, df	= 4 (P	= 0.12); I	² = 45%	6		
Test for overall effect: Z = 0.92 (P = 0.36)	``					
1.1.2 Opioid Acetaminophen C	ombinatio	on					
Lee 2013	49	125	37	120	11.8%	1.27 [0.90, 1.80]	+ - -
Peloso 2004	79	163	34	165	12.0%	2.35 [1.68, 3.30]	
Ruoff 2003	82	151	57	146	14.0%	1.39 [1.08, 1.79]	T
Subtotal (95% CI)		439		431	37.8%	1.60 [1.12, 2.28]	•
Total events	210		128				
Heterogeneity: Tau ² = 0.07; Chi ²	= 7.90, df	= 2 (P	= 0.02); I	² = 75%	6		
Test for overall effect: Z = 2.59 (P = 0.010)						
Total (95% CI)		1712		996	100.0%	1.26 [1.02, 1.55]	◆
Total events	660		318				
Heterogeneity: Tau ² = 0.06; Chi ²	= 24.72, c	lf = 7 (F	⊃ = 0.000	8); l² =	72%		
Test for overall effect: Z = 2.19 (P = 0.03)						0.01 0.1 1 10 10
Test for subgroup differences: C	,		(D - 0 07	12 - 7	0.40/		Favours [Placebo] Favours [Opioids]

Figure 6.2: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less. (Post hoc analysis)

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Lee 2013	49	125	37	120	43.7%	1.27 [0.90, 1.80]	+ = -
Uberall 2012	52	116	57	120	56.3%	0.94 [0.72, 1.24]	+
Total (95% CI)		241		240	100.0%	1.08 [0.80, 1.44]	•
Total events	101		94				
Heterogeneity: Tau ² =	0.02; Chi ²	= 1.76	, df = 1 (F	P = 0.18	3); I ² = 43%	0	
Test for overall effect:	Z = 0.49 (I	⊃ = 0.6	3)				0.01 0.1 1 10 100 Favours [Placebo] Favours [Opioids]

Figure 6.3: Opioids versus placebo; Outcome: Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater. (Post hoc analysis)





Figure 6.4: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

	Opioi	ds	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% CI
1.27.1 Public Funding							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applic	able						
1.27.2 Industry Funding							
Buynak 2010 (Oxycodone)	99	328	43	160	12.8%	1.12 [0.83, 1.52]	+-
Buynak 2010 (Tapentadol)	125	318	43	159	13.1%	1.45 [1.09, 1.94]	
Cristoph 2017 (Cebranopadol)	117	385	23	63	11.5%	0.83 [0.58, 1.19]	
Cristoph 2017 (Tapentadol)	57	126	24	63	11.3%	1.19 [0.82, 1.72]	+
Lee 2013	49	125	37	120	11.8%	1.27 [0.90, 1.80]	
Peloso 2004	79	163	34	165	12.0%	2.35 [1.68, 3.30]	-
Ruoff 2003	82	151	57	146	14.0%	1.39 [1.08, 1.79]	-
Uberall 2012	52	116	57	120	13.4%	0.94 [0.72, 1.24]	+
Subtotal (95% CI)		1712		996	100.0%	1.26 [1.02, 1.55]	◆
Total events	660		318				
Heterogeneity: Tau ² = 0.06; Chi ²	= 24.72, 0	if = 7 (F	P = 0.000	8); I² =	72%		
Test for overall effect: Z = 2.19 (P = 0.03)						
Total (95% CI)		1712		996	100.0%	1.26 [1.02, 1.55]	◆
Total events	660		318				
Heterogeneity: Tau ² = 0.06; Chi ²	= 24.72, 0	if = 7 (I	P = 0.000	8); l² =	72%		
Test for overall effect: Z = 2.19 (`					0.01 0.1 1 10 100 Equation [Blacebal] Equation [Opicida]
Test for subgroup differences: N	ot applical	ole					Favours [Placebo] Favours [Opioids]

Figure 6.5: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) (post hoc analysis)

For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)



SNRIs

Figure 7.1: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningful response to treatment.

	SNR	a l	Contr	ol		Risk Ratio		Risk	Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Rand	lom, 95	% CI	
Konno 2016	159	232	118	226	42.6%	1.31 [1.13, 1.53]					
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	6.5%	1.33 [0.90, 1.97]					
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	4.4%	0.93 [0.58, 1.50]		_	+		
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	6.3%	1.23 [0.83, 1.82]		-	-		
Skljarevski 2010	111	198	97	203	27.5%	1.17 [0.97, 1.42]			-		
Skljarevski 2010a	61	115	48	121	12.7%	1.34 [1.01, 1.77]			-		
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]			•		
Total events	482		314								
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df	= 5 (P = 0.	.76); l² :	= 0%						<u> </u>		
Test for overall effect: Z = 4.44 (P < 0.0000	1)	- 1					0.01	I 0.1 Favours [placebo]	Favou	10 rs [SNRI]	100

Figure 7.2: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater. (Post hoc analysis)

	SNR	1	Placel	00		Risk Ratio		Risk	<pre></pre>		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	I	M-H, Ran	dom, 95	5% CI	
Konno 2016	159	232	118	226	42.6%	1.31 [1.13, 1.53]					
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	6.5%	1.33 [0.90, 1.97]			+		
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	4.4%	0.93 [0.58, 1.50]		_	+-		
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	6.3%	1.23 [0.83, 1.82]			+		
Skljarevski 2010	111	198	97	203	27.5%	1.17 [0.97, 1.42]			-		
Skljarevski 2010a	61	115	48	121	12.7%	1.34 [1.01, 1.77]			-		
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]			•		
Total events	482		314								
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df =	= 5 (P = 0.	.76); l² :	= 0%				0.01	0.1	+	10	100
Test for overall effect: Z = 4.44 (P < 0.0000	1)						0.01	Favours [placebo]	Favou	urs [SNRI]	100

Figure 7.3: SNRIs (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding) (Post hoc analysis)

	SNR	I	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
1.14.1 Public Funding							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
1.14.2 Industry Funding							
Konno 2016	159	232	118	226	42.6%	1.31 [1.13, 1.53]	
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	6.5%	1.33 [0.90, 1.97]	+
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	4.4%	0.93 [0.58, 1.50]	-+-
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	6.3%	1.23 [0.83, 1.82]	
Skljarevski 2010	111	198	97	203	27.5%	1.17 [0.97, 1.42]	· · · · · · · · · · · · · · · · · · ·
Skljarevski 2010a	61	115	48	121	12.7%	1.34 [1.01, 1.77]	
Subtotal (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	•
Total events	482		314				
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df =	5 (P = 0.	76); l² :	= 0%				
Test for overall effect: Z = 4.44 (P < 0.00001)						
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	*
Total events	482		314				
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df =	5 (P = 0.	76); l² :	= 0%				
Test for overall effect: Z = 4.44 (P < 0.00001)						0.01 0.1 1 10 100 Favours [placebo] Favours [SNRI]
Test for subgroup differences: Not applicable	9						Tavouis (placebo) Favouis (SINRI)

Figure 7.4: SNRIs (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) (post hoc analysis) For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)

	SNR	1	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
1.15.1 Less than the median risk of bias s	core						
Konno 2016 Subtotal (95% CI)	159	232 232	118	226 226	42.6% 42.6%	1.31 [1.13, 1.53] 1.31 [1.13, 1.53]	•
Total events Heterogeneity: Not applicable Test for overall effect: Z = 3.50 (P = 0.0005)	159		118				
1.15.2 Greater than or equal to the media	n risk of I	bias sc	ore				
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	6.5%	1.33 [0.90, 1.97]	+
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	4.4%	0.93 [0.58, 1.50]	-+-
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	6.3%	1.23 [0.83, 1.82]	
Skljarevski 2010	111	198	97	203	27.5%	1.17 [0.97, 1.42]	-
Skljarevski 2010a Subtotal (95% Cl)	61	115 600	48	121 441	12.7% 57.4%	1.34 [1.01, 1.77] 1.21 [1.06, 1.38]	•
Total events	323		196				
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 2.00$, $df =$ Test for overall effect: Z = 2.84 (P = 0.004)	4 (P = 0.	74); l² =	= 0%				
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	•
Total events Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df = Test for overall effect: Z = 4.44 (P < 0.00001 Test for subgroup differences: Chi ² = 0.64, d)	,.					0.01 0.1 1 10 100 Favours [placebo] Favours [SNRI]

Corticosteroid Injections

Figure 8.1: Corticosteroid injections versus saline injections; Outcome: Proportion of patients with a meaningful response to treatment.




Figure 8.2: Corticosteroid injections versus saline injections; Outcome: Proportion of patients with a meaningful response to treatment at 4 weeks or less

	Corticoste	roids	Salin	ie		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Rand	lom, 95% Cl	
Arden 2005	15	120	4	108	13.6%	3.38 [1.16, 9.86]				
Carette 1997	15	78	13	80	21.1%	1.18 [0.60, 2.32]				
Ghahreman 2010	8	14	2	13	10.1%	3.71 [0.96, 14.37]				
Nguyen 2017	36	67	21	68	27.1%	1.74 [1.14, 2.65]				
Saqib 2016	25	54	30	55	28.1%	0.85 [0.58, 1.24]			+	
Total (95% CI)		333		324	100.0%	1.55 [0.93, 2.59]			•	
Total events	99		70							
Heterogeneity: Tau ² =	0.21; Chi ² =	12.81, d	f = 4 (P =	0.01);	l² = 69%					100
Test for overall effect:							0.01	0.1 Favours [Saline]	1 10 Favours [Cortico	100 [steroids]

Figure 8.3: Corticosteroid injections versus saline injections; Outcome: Outcome: Proportion of patients with a meaningful response to treatment at 12 weeks or greater.

	Corticoste	eroids	Salin	e		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Arden 2005	39	120	32	108	13.0%	1.10 [0.74, 1.62]	
Carette 1997	29	78	33	80	13.0%	0.90 [0.61, 1.33]	
Ghai 2015	30	35	17	34	13.8%	1.71 [1.19, 2.46]	
Manchikanti 2012	25	50	29	50	13.8%	0.86 [0.60, 1.24]	
Manchikanti 2012a	43	60	37	60	17.6%	1.16 [0.90, 1.50]	+
Manchikanti 2014	40	60	45	60	18.6%	0.89 [0.71, 1.12]	-
Ng 2005	15	43	24	43	10.3%	0.63 [0.38, 1.02]	
Total (95% CI)		446		435	100.0%	1.01 [0.82, 1.24]	•
Total events	221		217				
Heterogeneity: Tau ² =	0.05; Chi ² =	15.52, d	f = 6 (P =	0.02);	l² = 61%	E.	
Test for overall effect:				,,		0.0	01 0.1 1 10 100 Favours [Saline] Favours [Corticosteroids]

Figure 8.4: Corticosteroid injections versus saline injections; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study funding source (public or industry funding)





Figure 8.5: Corticosteroid injections versus saline injections; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by median risk of bias (less than the median risk of bias score or greater than or equal to the median risk of bias score) For each study, the risk of bias domain was scored (0=low risk, 1=unclear risk, 2=high risk) and a median was found among all the studies within each intervention. Studies were then divided into two categories: less than the median or greater than or equal to the median. (Higgins 2011)



Post Hoc Analysis

I. Fixed Effects Analysis

Figure 9.1: Exercise versus no exercise; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	Exerc	ise	No Exe	rcise		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Albaledejo 2010	77	100	115	139	24.8%	0.93 [0.82, 1.06]	=
Brandt 2015	3	5	1	7	0.2%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	4.1%	1.09 [0.67, 1.79]	_
Chan 2017	27	50	13	46	3.5%	1.91 [1.13, 3.24]	— -
Cox 2010	4	10	5	10	1.3%	0.80 [0.30, 2.13]	
Ford 2016	99	156	49	144	13.1%	1.86 [1.44, 2.41]	
Frost 2004	93	144	64	142	16.6%	1.43 [1.15, 1.78]	-
Groessl 2017	33	75	25	75	6.4%	1.32 [0.88, 1.99]	+ - -
Hall 2011	37	80	12	80	3.1%	3.08 [1.74, 5.47]	
Hartvigsen 2010a	10	45	4	23	1.4%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	1.4%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	1.8%	2.71 [1.32, 5.60]	
Jensen 2012	9	49	4	51	1.0%	2.34 [0.77, 7.11]	+
Moffett 1999	47	89	30	98	7.4%	1.73 [1.21, 2.47]	
Natour 2015	7	30	4	30	1.0%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	0.5%	4.67 [1.23, 17.68]	· · · · · · · · · · · · · · · · · · ·
Saper 2017a	44	127	7	32	2.9%	1.58 [0.79, 3.18]	+
Saper 2017b	48	129	8	32	3.3%	1.49 [0.78, 2.82]	+
Sherman 2005a	25	36	4	15	1.5%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	1.8%	1.54 [0.70, 3.38]	+
Sherman 2011a	55	92	4	22	1.7%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	1.2%	3.54 [1.20, 10.40]	
Total (95% CI)		1472		1089	100.0%	1.56 [1.42, 1.72]	•
Total events	734		386				
Heterogeneity: Chi ² = Test for overall effect)001); I [:]	² = 75%		0.01 0.1 1 10 10 Favours no exercise Favours exercise

Figure 9.2: Acupuncture versus control; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	Acupun	cture	Cont	rol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M–H, Fixed, 95% Cl	M–H, Fixed, 95% (21
Brinkhaus 2006	76	146	27	73	4.5%	1.41 [1.00, 1.97]		
Cherkin 2009	150	315	80	162	13.3%	0.96 [0.79, 1.17]	+	
Coan 1980	15	25	6	25	0.8%	2.50 [1.16, 5.39]		-
Haake 2007	304	387	277	387	34.8%	1.10 [1.01, 1.19]	•	
Meng 2003	7	28	1	23	0.1%	5.75 [0.76, 43.41]	+	·
Molsberger 1998	39	65	20	61	2.6%	1.83 [1.21, 2.76]		
Qin 2019	18	40	9	40	1.1%	2.00 [1.02, 3.91]		
Witt 2006	711	1451	334	1390	42.8%	2.04 [1.83, 2.27]		
Total (95% CI)		2457		2161	100.0%	1.54 [1.45, 1.65]	•	
Total events	1320		754					
Heterogeneity: Chi ² =	= 120.27,	df = 7 (I	P < 0.00	001); I ²	= 94%			10 100
Test for overall effect	:: Z = 13.0	1 (P < 0	0.00001)				0.01 0.1 1 Favours control Favours	10 100 acupuncture

Figure 9.3: Spinal Manipulation versus control; Outcome: Proportion of patients with a meaningful response to treatment Oral NSAIDs (fixed effects analysis)

	Spinal Manipu	lation	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Bialosky 2014	7	28	6	27	4.6%	1.13 [0.43, 2.92]	
Bond 2020	6	14	7	15	5.1%	0.92 [0.41, 2.07]	
Ford 2019	28	33	11	31	8.5%	2.39 [1.46, 3.93]	
Goertz 2017	13	44	5	39	4.0%	2.30 [0.90, 5.88]	
Licciardone 2013	145	230	103	225	77.9%	1.38 [1.16, 1.64]	
Total (95% CI)		349		337	100.0%	1.47 [1.25, 1.71]	•
Total events	199		132				
Heterogeneity: Chi ² =	= 6.70, df = 4 (P	= 0.15);	$I^2 = 40\%$				
Test for overall effect	z = 4.76 (P < 0)	0.00001)					0.01 0.1 1 10 100 Favours control Favours manipulation

Figure 9.4: Oral NSAIDs versus placebo; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	NSAII	Ds	Conti	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Coats 2004	96	148	77	145	27.9%	1.22 [1.01, 1.48]	-
Katz 2003a	149	233	39	114	18.8%	1.87 [1.42, 2.45]	-
Katz 2003b	142	229	39	114	18.7%	1.81 [1.38, 2.38]	-
Katz 2011	45	88	20	41	9.8%	1.05 [0.72, 1.52]	
Kivitz 2013	111	295	62	230	25.0%	1.40 [1.08, 1.81]	-
Total (95% CI)		993		644	100.0%	1.48 [1.32, 1.66]	•
Total events	543		237				
Heterogeneity: Chi ² =	= 12.16, d	f = 4 (1)	P = 0.02)); $I^2 = 6$	7%		
Test for overall effect	:: Z = 6.55	5 (P < 0	0.00001)				0.01 0.1 1 10 100 Favours control Favours NSAIDs

Figure 9.5: Rubefacients versus placebo; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	Rubefac	ients	Place	bo		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fix	ed, 95% Cl	
Chrubasik 2010	52	71	35	71	24.8%	1.49 [1.13, 1.96]				
Frerick 2003	98	159	75	160	52.9%	1.31 [1.07, 1.61]				
Keitel 2001	45	74	32	76	22.3%	1.44 [1.05, 1.99]				
Total (95% CI)		304		307	100.0%	1.39 [1.20, 1.61]			•	
Total events	195		142							
Heterogeneity: Chi ² =	0.56, df = 2	(P = 0.	76); l² = 0	%				01		100
Test for overall effect:	Z = 4.36 (F	P < 0.000	01)				0.01	0.1 Favours [Placebo]	1 10 Favours [Rubefa	100 acients]

Figure 9.6: Opioids versus placebo; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
1.1.1 Opioid Only							
Buynak 2010 (Oxycodone)	99	328	43	160	15.5%	1.12 [0.83, 1.52]	
Buynak 2010 (Tapentadol)	125	318	43	159	15.4%	1.45 [1.09, 1.94]	
Cristoph 2017 (Cebranopadol)	117	385	23	63	10.6%	0.83 [0.58, 1.19]	
Cristoph 2017 (Tapentadol)	57	126	24	63	8.6%	1.19 [0.82, 1.72]	
Lee 2013	49	125	37	120	10.1%	1.27 [0.90, 1.80]	
Uberall 2012	52	116	57	120	15.1%	0.94 [0.72, 1.24]	-
Subtotal (95% CI)		1398		685	75.3%	1.14 [1.00, 1.30]	♦
Total events	499		227				
Test for overall effect: Z = 1.99	, ,	,.					
1.1.2 Opioid Acetaminophen							
Peloso 2004	79	163	34	165	9.1%	2.35 [1.68, 3.30]	
Ruoff 2003	82	151	57	146	15.6%	1.39 [1.08, 1.79]	
Subtotal (95% CI)		314		311	24.7%	1.74 [1.43, 2.14]	
Total events	161		91				
Heterogeneity: Chi ² = 6.14, df = Test for overall effect: Z = 5.40	•		84%				
		1712		996	100.0%	1.29 [1.16, 1.44]	•
Total (95% CI)							
Total (95% CI) Total events	660		318				
()		0008);					
Total events	= 7 (P = 0.0	<i>,</i> .					0.01 0.1 1 10 10 Favours [Placebo] Favours [Opioids]

Figure 9.7: SNRIs (duloxetine) versus placebo; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	SNR	1	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Konno 2016	159	232	118	226	35.9%	1.31 [1.13, 1.53]	=
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	7.6%	1.33 [0.90, 1.97]	
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	6.1%	0.93 [0.58, 1.50]	-
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	7.6%	1.23 [0.83, 1.82]	
Skljarevski 2010	111	198	97	203	28.7%	1.17 [0.97, 1.42]	
Skljarevski 2010a	61	115	48	121	14.0%	1.34 [1.01, 1.77]	-
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	♦
Total events	482		314				
Heterogeneity: Chi ² = 2.64, df = 5 (P = 0.76	; I² = 0%						
Test for overall effect: Z = 4.33 (P < 0.0001)							0.01 0.1 1 10 100 Favours [placebo] Favours [SNRI]

Figure 9.8: Corticosteroid injections versus saline injections; Outcome: Proportion of patients with a meaningful response to treatment (fixed effects analysis)

	Corticoste	roids	Salin	е		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	CI M-H, Fixed, 95% CI
Arden 2005	39	120	32	108	13.0%	1.10 [0.74, 1.62]	·
Carette 1997	29	78	33	80	12.6%	0.90 [0.61, 1.33]	
Ghahreman 2010	8	14	2	13	0.8%	3.71 [0.96, 14.37]	
Ghai 2015	31	35	20	34	7.9%	1.51 [1.11, 2.04]	-
Manchikanti 2012	23	50	24	50	9.3%	0.96 [0.63, 1.45]	· _+
Manchikanti 2012a	36	60	32	60	12.4%	1.13 [0.82, 1.54]	
Manchikanti 2014	34	60	39	60	15.1%	0.87 [0.65, 1.16]	
Ng 2005	15	43	24	43	9.3%	0.63 [0.38, 1.02]	
Nguyen 2017	36	67	21	68	8.1%	1.74 [1.14, 2.65]	
Saqib 2016	25	54	30	55	11.5%	0.85 [0.58, 1.24]	-
Total (95% CI)		581		571	100.0%	1.06 [0.94, 1.20]	•
Total events	276		257				
Heterogeneity: Chi ² =	22.42, df = 9	(P = 0.0	08); l² = 6	60%			
Test for overall effect:		·					0.01 0.1 1 10 100 Favours [Saline] Favours [Corticosteroids]

II. Subgroup analysis by control group characteristics (sham versus non-sham procedures or prescribed versus passive exercise controls)

Figures 10.1: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by control group characteristics (prescribed versus passive exercise controls)

	Exerc		No Exe			Risk Ratio	Risk Ratio
Study or Subgroup			Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
1.10.1 Passive Cont	rol Group	S					
Albaledejo 2010	77	100	115	139	8.0%	0.93 [0.82, 1.06]	-
Brandt 2015	3	5	1	7	1.2%	4.20 [0.60, 29.54]	
Cox 2010	4	10	5	10	3.2%	0.80 [0.30, 2.13]	
Frost 2004	93	144	64	142	7.7%	1.43 [1.15, 1.78]	-
Groessl 2017	33	75	25	75	6.5%	1.32 [0.88, 1.99]	
Hall 2011	37	80	12	80	5.4%	3.08 [1.74, 5.47]	
Hartvigsen 2010a	10	45	4	23	3.0%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	3.0%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	4.5%	2.71 [1.32, 5.60]	
Moffett 1999	47	89	30	98	6.9%	1.73 [1.21, 2.47]	
Natour 2015	7	30	4	30	2.7%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	2.1%	4.67 [1.23, 17.68]	
Saper 2017a	44	127	7	32	4.6%	1.58 [0.79, 3.18]	+
Saper 2017b	48	129	8	32	5.0%	1.49 [0.78, 2.82]	+
Sherman 2005a	25	36	4	15	3.7%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	4.1%	1.54 [0.70, 3.38]	
Sherman 2011a	55	92	4	22	3.6%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	2.9%	3.54 [1.20, 10.40]	
Subtotal (95% CI)		1183		813	78.1%	1.74 [1.33, 2.29]	•
Total events	582		304				
Heterogeneity: Tau ²	= 0.19; Cł	1i ² = 74	4.18, df =	= 17 (P	< 0.0000	1); $I^2 = 77\%$	
Test for overall effec	t: Z = 4.02	L (P < C).0001)				
1.10.2 Prescribed Co	ontrol Gra	nuns					
Brodsky 2019	17	34	16	35	5.9%	1.09 [0.67, 1.79]	
Chan 2017	27	50	13	46	5.7%	1.91 [1.13, 3.24]	
Ford 2016	27 99	156	49	144	7.5%	1.86 [1.44, 2.41]	
ensen 2012	99	49	49	51	2.8%	2.34 [0.77, 7.11]	
Subtotal (95% CI)	9	289	4	276	2.8% 21.9%	1.68 [1.27, 2.21]	
Total events	152	200	82	_/0	- 1.570	1.00 [1127, 2121]	•
Heterogeneity: Tau ²		$ni^2 - 4$		3 (P - () 25)· 1 ² -	27%	
Test for overall effec				5 (1 – (J.2J), T =	27/0	
Total (95% CI)		1472		1089	100.0%	1.71 [1.37, 2.15]	
Total events	734		386		/•		•
Heterogeneity: Tau ²		ni ² — 01		- 21 (P	~ 0 0000	1): $I^2 - 75\%$	
Test for overall effect				- 21 (P	< 0.0000	1/, 1 = 7.5/0	0.01 0.1 1 10 1
							Favours no exercise Favours exercise

Figure 10.2: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by control group characteristics (sham versus non-sham procedures)

	Acupun	cture	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
1.1.1 Non-Sham Cont	trol						
Coan 1980	15	25	6	25	9.0%	2.50 [1.16, 5.39]	_ _
Meng 2003	7	28	1	23	2.4%	5.75 [0.76, 43.41]	+
Witt 2006	711	1451	334	1390	16.9%	2.04 [1.83, 2.27]	
Subtotal (95% CI)		1504		1438	28.3%	2.05 [1.85, 2.28]	♦
Total events	733		341				
Heterogeneity: Tau ² =	0.00; Chi ²	= 1.27, d	df = 2 (P =	= 0.53);	l² = 0%		
Test for overall effect:	Z = 13.30 (P < 0.00	0001)				
1.1.2 Sham Control							
Brinkhaus 2006	76	146	27	73	14.6%	1.41 [1.00, 1.97]	
Cherkin 2009	150	315	80	162	16.2%	0.96 [0.79, 1.17]	+
Haake 2007	304	387	277	387	17.0%	1.10 [1.01, 1.19]	•
Molsberger 1998	39	65	20	61	13.7%	1.83 [1.21, 2.76]	
Qin 2019	18	40	9	40	10.2%	2.00 [1.02, 3.91]	
Subtotal (95% CI)		953		723	71.7%	1.25 [1.02, 1.54]	◆
Total events	587		413				
Heterogeneity: Tau ² =	0.03; Chi ²	= 13.09,	df = 4 (P	= 0.01); l ² = 69%	D	
Test for overall effect:	Z = 2.11 (F	P = 0.03)					
Total (95% CI)		2457		2161	100.0%	1.58 [1.13, 2.21]	◆
Total events	1320		754				
Heterogeneity: Tau ² =	0.17; Chi ²	= 120.23	7, df = 7 (P < 0.0	0001); l² =	= 94%	
Test for overall effect:					,,		0.01 0.1 1 10 10
Test for subgroup diffe	· ·		,	(P < 0.	0001), l² =	94.2%	Favours control Favours acupuncture

Figure 10.3: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by control group characteristics (sham versus non-sham procedures)

	Spinal Manipu	lation	Conti	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.5.1 Non-Sham Cor	ntrol						
Ford 2019	28	33	11	31	23.4%	2.39 [1.46, 3.93]	
Goertz 2017	13	44	5	39	9.6%	2.30 [0.90, 5.88]	
Subtotal (95% CI)		77		70	33.0%	2.37 [1.53, 3.68]	•
Total events	41		16				
Heterogeneity: Tau ² =	= 0.00; Chi ² = 0.0	00, df =	1 (P = 0.	94); I ²	= 0%		
Test for overall effect	Z = 3.86 (P = 0)	.0001)					
1.5.2 Sham Control							
Bialosky 2014	7	28	6	27	9.4%	1.13 [0.43, 2.92]	
Bond 2020	6	14	7	15	12.1%	0.92 [0.41, 2.07]	_
Licciardone 2013	145	230	103	225	45.5%	1.38 [1.16, 1.64]	≡
Subtotal (95% CI)		272		267	67.0%	1.35 [1.14, 1.59]	◆
Total events	158		116				
Heterogeneity: Tau ² =	= 0.00; Chi ² = 1.0	06, df =	2 (P = 0.	59); I ²	= 0%		
Test for overall effect	Z = 3.49 (P = 0)	.0005)					
Total (95% CI)		349		337	100.0%	1.54 [1.11, 2.12]	◆
Total events	199		132				
Heterogeneity: Tau ² =	= 0.05; Chi ² = 6.3	70, df =	4 (P = 0.	15); I ²	= 40%		0.01 0.1 1 10 10
Test for overall effect	Z = 2.62 (P = 0)	.009)					Favours control Favours manipulation
Test for subgroup dif	ferences: Chi ² =	5.61, df	= 1 (P =	0.02),	$I^2 = 82.2$	%	ravours control ravours manipulation

III. Subgroup analysis by trial size

Figures 11.1: Exercise versus no exercise; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)

	Exerc	ise	No Exe	No Exercise		Risk Ratio	Risk Ratio
Study or Subgroup			M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl			
1.9.1 Studies (>150)							
Albaledejo 2010	77	100	115	139	24.8%	0.93 [0.82, 1.06]	=
Ford 2016	99	156	49	144	13.1%	1.86 [1.44, 2.41]	-
Frost 2004	93	144	64	142	16.6%	1.43 [1.15, 1.78]	+
Hall 2011	37	80	12	80	3.1%	3.08 [1.74, 5.47]	
Moffett 1999	47	89	30	98	7.4%	1.73 [1.21, 2.47]	
Saper 2017a	44	127	7	32	2.9%	1.58 [0.79, 3.18]	+
Saper 2017b Subtotal (95% CI)	48	129 825	8	32 667	3.3% 71.2%	1.49 [0.78, 2.82] 1.45 [1.30, 1.61]	
Total events	445	025	285	007	11.2/0	1.45 [1.50, 1.01]	•
Heterogeneity: Chi ² =		f - 6 (10.11.12	200/		
Test for overall effect:				JUT), I-	- 09%		
rescior overall effect:	z = 0.70	ט (ד < נ					
1.9.2 Studies (<=150))						
Brandt 2015	3	5	1	7	0.2%	4.20 [0.60, 29.54]	
Brodsky 2019	17	34	16	35	4.1%	1.09 [0.67, 1.79]	
Chan 2017	27	50	13	46	3.5%	1.91 [1.13, 3.24]	_
Cox 2010	4	10	5	10	1.3%	0.80 [0.30, 2.13]	
Groessl 2017	33	75	25	75	6.4%	1.32 [0.88, 1.99]	+
Hartvigsen 2010a	10	45	4	23	1.4%	1.28 [0.45, 3.63]	
Hartvigsen 2010b	10	46	4	22	1.4%	1.20 [0.42, 3.39]	
Highland 2018	19	34	7	34	1.8%	2.71 [1.32, 5.60]	
Jensen 2012	9	49	4	51	1.0%	2.34 [0.77, 7.11]	
Natour 2015	7	30	4	30	1.0%	1.75 [0.57, 5.36]	
Saper 2009	10	15	2	14	0.5%	4.67 [1.23, 17.68]	
Sherman 2005a	25	36	4	15	1.5%	2.60 [1.09, 6.20]	
Sherman 2005b	18	35	5	15	1.8%	1.54 [0.70, 3.38]	
Sherman 2011a	55	92	4	22	1.7%	3.29 [1.33, 8.10]	
Sherman 2011b	42	91	3	23	1.2%	3.54 [1.20, 10.40]	
Subtotal (95% CI)		647		422	28.8%	1.84 [1.51, 2.24]	•
Total events	289		101				
Heterogeneity: Chi ² =				$(9); ^2 = 2$	24%		
Test for overall effect:	Z = 6.00	0 (P < 0	0.00001)				
Total (95% CI)		1472		1089	100.0%	1.56 [1.42, 1.72]	◆
Total events	734		386				
Heterogeneity: Chi ² =	85.66. d	lf = 21		0001); l ²	$^{2} = 75\%$		
Test for overall effect:				,, -	-		
Test for subgroup diff				- 1 (P -	- 0.04) 18	2 - 76 6%	Favours no exercise Favours exercise


Figures 11.2: Acupuncture versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)

	Acupun	cture	Conti	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
1.8.1 Studies (>150)							
Brinkhaus 2006	76	146	27	73	14.6%	1.41 [1.00, 1.97]	⊢ ∎
Cherkin 2009	150	315	80	162	16.2%	0.96 [0.79, 1.17]	+
Haake 2007	304	387	277	387	17.0%	1.10 [1.01, 1.19]	
Witt 2006	711	1451	334	1390	16.9%	2.04 [1.83, 2.27]	-
Subtotal (95% CI)		2299		2012	64.7%	1.32 [0.86, 2.02]	•
Total events	1241		718				
Heterogeneity: $Tau^2 =$	0.18; Ch	$i^2 = 110$	0.78, df =	= 3 (P <	< 0.00001	L); $I^2 = 97\%$	
Test for overall effect:							
1.8.2 Studies (<=150))						
Coan 1980	15	25	6	25	9.0%	2.50 [1.16, 5.39]	
Meng 2003	7	28	1	23	2.4%	5.75 [0.76, 43.41]	· · · · · · · · · · · · · · · · · · ·
Molsberger 1998	39	65	20	61	13.7%	1.83 [1.21, 2.76]	
Qin 2019	18	40	9	40	10.2%	2.00 [1.02, 3.91]	
Subtotal (95% CI)		158		149	35.3%	2.02 [1.48, 2.77]	•
Total events	79		36				
Heterogeneity: $Tau^2 =$	0.00; Ch	$i^2 = 1.6$	0, df = 3	(P = 0)	.66); $I^2 =$	0%	
Test for overall effect:							
Total (95% CI)		2457		2161	100.0%	1.58 [1.13, 2.21]	\bullet
Total events	1320		754				
Heterogeneity: $Tau^2 =$	0.17; Ch	$i^2 = 120$	0.27, df =	= 7 (P <	< 0.00001	l); $I^2 = 94\%$	0.01 0.1 1 10 100
Test for overall effect:	Z = 2.68	(P = 0.	007)				
Test for subgroup diff				- 1 (P -	0 1 1) 12	- 60.0%	Favours control Favours acupuncture

Figures 11.3: Spinal Manipulation versus control; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to \geq 150 participants)

	Spinal Manipu	lation	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.7.1 Studies (>150)							
Licciardone 2013 Subtotal (95% Cl)	145	230 230	103	225 225	45.5% 45.5%	1.38 [1.16, 1.64] 1.38 [1.16, 1.64]	
Total events	145		103				
Heterogeneity: Not app	plicable						
Test for overall effect:	Z = 3.62 (P = 0)	0.0003)					
1.7.2 Studies (<=150)						
Bialosky 2014	7	28	6	27	9.4%	1.13 [0.43, 2.92]	
Bond 2020	6	14	7	15	12.1%	0.92 [0.41, 2.07]	
Ford 2019	28	33	11	31	23.4%	2.39 [1.46, 3.93]	
Goertz 2017	13	44	5	39	9.6%	2.30 [0.90, 5.88]	
Subtotal (95% CI)		119		112	54.5%	1.64 [1.00, 2.71]	◆
Total events	54		29				
Heterogeneity: Tau ² =	0.11; $Chi^2 = 5$.	10, df =	3 (P = 0.	16); I ²	= 41%		
Test for overall effect:	Z = 1.95 (P = 0)	0.05)					
Total (95% CI)		349		337	100.0%	1.54 [1.11, 2.12]	◆
Total events Heterogeneity: Tau ² = Test for overall effect:			132 4 (P = 0.	15); I²	= 40%		
Test for subgroup diffe	,	,	= 1 (P =	0.51),	$I^2 = 0\%$		Favours control Favours manipulation

Figures 11.4: Oral NSAIDs versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to \geq 150 participants)



Figures 11.5: Rubefacients versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)

	Rubefaci	ients	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.11.1 Studies (>150)							
Frerick 2003	98	159	75	160	50.7%	1.31 [1.07, 1.61]	=
Subtotal (95% CI)		159		160	50.7%	1.31 [1.07, 1.61]	◆
Total events	98		75				
Heterogeneity: Not app	licable						
Test for overall effect: Z	z = 2.61 (P	9 = 0.009	9)				
1.11.2 Studies (<=150))						
Chrubasik 2010	52	71	35	71	28.4%	1.49 [1.13, 1.96]	
Keitel 2001	45	74	32	76	20.8%	1.44 [1.05, 1.99]	-
Subtotal (95% CI)		145		147	49.3%	1.47 [1.19, 1.81]	◆
Total events	97		67				
Heterogeneity: Tau ² = 0).00; Chi² =	= 0.02, d	df = 1 (P =	= 0.90);	l² = 0%		
Test for overall effect: Z	z = 3.61 (P	9 = 0.000	03)				
Total (95% CI)		304		307	100.0%	1.39 [1.20, 1.61]	•
Total events	195		142				
Heterogeneity: Tau ² = 0	0.00; Chi² =	= 0.56, d	df = 2 (P =	= 0.76);	l ² = 0%		
Test for overall effect: Z	z = 4.39 (P	< 0.000)))				0.01 0.1 1 10 100 Favours [Placebo] Favours [Rubefacients]
Test for subgroup differ	ences: Ch	i² = 0.54	, df = 1 (P = 0.4	6), I² = 0%	5	

Figures 11.6: Opioids versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to ≥150 participants)

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.28.1 Studies (>150)							
Buynak 2010 (Oxycodone)	99	328	43	160	12.8%	1.12 [0.83, 1.52]	-
Buynak 2010 (Tapentadol)	125	318	43	159	13.1%	1.45 [1.09, 1.94]	
Cristoph 2017 (Cebranopadol)	117	385	23	63	11.5%	0.83 [0.58, 1.19]	
Cristoph 2017 (Tapentadol)	57	126	24	63	11.3%	1.19 [0.82, 1.72]	
Lee 2013	49	125	37	120	11.8%	1.27 [0.90, 1.80]	+=
Peloso 2004	79	163	34	165	12.0%	2.35 [1.68, 3.30]	-
Ruoff 2003	82	151	57	146	14.0%	1.39 [1.08, 1.79]	-
Uberall 2012	52	116	57	120	13.4%	0.94 [0.72, 1.24]	+
Subtotal (95% CI)		1712		996	100.0%	1.26 [1.02, 1.55]	◆
Total events	660		318				
Heterogeneity: Tau ² = 0.06; Chi ²	= 24.72, 6	df = 7 (I	P = 0.000	8); l² =	72%		
Test for overall effect: Z = 2.19 (P = 0.03)						
1.28.2 Studies (<=150)							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applic	able						
Total (95% CI)		1712		996	100.0%	1.26 [1.02, 1.55]	•
Total events	660		318				
Heterogeneity: Tau ² = 0.06; Chi ²	= 24.72.	df = 7 (I	P = 0.000	8): l² =	72%		
Test for overall effect: Z = 2.19 (<i>,</i> , ,			0.01 0.1 1 10 100
Test for subgroup differences: N	,	ble					Favours [Placebo] Favours [Opioids]

Figures 11.7: SNRI (duloxetine) versus placebo; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to \geq 150 participants)

	SNR	1	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
1.16.1 Studies (>150)							
Konno 2016	159	232	118	226	42.6%	1.31 [1.13, 1.53]	
Sklijarevski 2009 (Duloxetine 120mg/day)	65	112	17	39	6.5%	1.33 [0.90, 1.97]	+
Sklijarevski 2009 (Duloxetine 20mg/day)	24	59	17	39	4.4%	0.93 [0.58, 1.50]	_ _ _
Sklijarevski 2009 (Duloxetine 60mg/day)	62	116	17	39	6.3%	1.23 [0.83, 1.82]	+
Skljarevski 2010	111	198	97	203	27.5%	1.17 [0.97, 1.42]	-
Skljarevski 2010a	61	115	48	121	12.7%	1.34 [1.01, 1.77]	
Subtotal (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	•
Total events	482		314				
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df =	5 (P = 0.	76); l² :	= 0%				
Test for overall effect: $Z = 4.44$ (P < 0.00001)							
1.16.2 Studies (<=150)							
Subtotal (95% CI)		0		0		Not estimable	
Total events	0		0				
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Total (95% CI)		832		667	100.0%	1.25 [1.13, 1.38]	•
Total events	482		314				
Heterogeneity: Tau ² = 0.00; Chi ² = 2.64, df =	5 (P = 0.	76); l² :	= 0%				
Test for overall effect: Z = 4.44 (P < 0.00001)							0.01 0.1 1 10 10 Favours [placebo] Favours [SNRI]
Test for subgroup differences: Not applicable							Favouis [placebo] Favouis [SINRI]

Figures 11.8: Corticosteroid Injections versus saline injections; Subgroup analysis: Proportion of patients with a meaningful response to treatment, analyzed by study size (<150 participants compared to \geq 150 participants)

	Corticoste	roids	Salin	е		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.13.1 Studies (>150)							
Arden 2005	39	120	32	108	10.6%	1.10 [0.74, 1.62]	-
Carette 1997	29	78	33	80	10.5%	0.90 [0.61, 1.33]	
Subtotal (95% CI)		198		188	21.1%	0.99 [0.76, 1.31]	•
Total events	68		65				
Heterogeneity: Tau ² = 0	0.00; Chi² = ().49, df	= 1 (P = 0).48); l²	= 0%		
Test for overall effect: 2	Z = 0.04 (P =	0.97)					
1.13.2 Studies (<=150))						
Ghahreman 2010	8	14	2	13	1.9%	3.71 [0.96, 14.37]	
Ghai 2015	31	35	20	34	12.5%	1.51 [1.11, 2.04]	
Manchikanti 2012	23	50	24	50	10.0%	0.96 [0.63, 1.45]	
Manchikanti 2012a	36	60	32	60	12.3%	1.13 [0.82, 1.54]	
Manchikanti 2014	34	60	39	60	12.9%	0.87 [0.65, 1.16]	
Ng 2005	15	43	24	43	8.6%	0.63 [0.38, 1.02]	
Nguyen 2017	36	67	21	68	9.9%	1.74 [1.14, 2.65]	
Saqib 2016	25	54	30	55	10.9%	0.85 [0.58, 1.24]	
Subtotal (95% CI)		383		383	78.9%	1.09 [0.85, 1.40]	◆
Total events	208		192				
Heterogeneity: Tau ² = (0.08; Chi² = 2	21.63, d	f = 7 (P =	0.003)	l² = 68%		
Test for overall effect: 2	Z = 0.68 (P =	0.49)					
Total (95% Cl)		581		571	100.0%	1.07 [0.87, 1.30]	
Total events	276		257				
Heterogeneity: Tau ² = 0	0.06; Chi² = 2	22.42, d	f = 9 (P =	0.008)	l ² = 60%		
Test for overall effect: 2	<u>z</u> = 0.64 (P =	0.52)				0.01	0.1 1 10 100
Test for subgroup differ		,	df = 1 (P :	= 0.63).	$ ^2 = 0\%$		Favours [Saline] Favours [Corticosteroids]

Adverse Events

Table 7: Overall Adverse Events

Ordered Intervention by in Alphabetical Order

Intervention Type	Type of Adverse Event	Randomized Controlled Trials	Intervention Control	# of RCTs	# of Participants	Intervention Event Rate	Control Event Rate	Risk Ratio (95% Confidence Interval)	NNH
Acupuncture	Adverse Events	Brinkhaus 2006	Acupuncture Minimal Acupuncture	1	219	10.3% (15/146)	16.4% (12/73)	RR 0.63 (95% Cl 0.31, 1.27)*	NSS
Acupuncture	Adverse Events	Cherkin 2009	Standardized Acupuncture + Individualized Acupuncture Simulated Acupuncture	1	477	3.8% (12/315)	0% (0/162)	RR 12.90 (95% Cl 0.77, 216.44)*	NSS
Acupuncture	Adverse Events	Kerr 2003	Acupuncture Placebo-TENS	1	60	6.7% (2/30)	6.7% (2/30)	RR 1.00 (95% Cl 0.15, 6.64)*	NSS
Acupuncture	Adverse Events	Meng 2003	Acupuncture + Standard Therapy Standard Therapy	1	51	32.1% (9/28)	26.1% (6/23)	RR 1.23 (95% Cl 0.51, 2.95)*	NSS
Acupuncture	Adverse Events	Qin 2019	Acupuncture Sham Acupuncture	1	80	7.5% (3/40)	12.5% (5/40)	RR 0.60 (95% Cl 0.15, 2.34)*	NSS
Acupuncture	Serious Adverse Events	Haake 2007	Verum Acupuncture Sham Acupuncture	1	774	3.1% (12/387)	3.1% (12/387)	RR 1.00 (95% Cl 0.45, 2.20)*	NSS

Acupuncture	Withdrawal due to Adverse Events	Qin 2019	Acupuncture Sham Acupuncture	1	80	2.5% (1/40)	0% (0/40)	RR 3.00 (95% Cl 0.13, 71.51)	NSS
Anticonvulsants	Loss of Balance	Atkinson 2016	Gabapentin (Mean 3265 mg)	1	108	33% (18/55)	4% (2/53)	RR 8.67 (95% Cl 2.11, 35.57)*	4
Anticonvulsants	Decreased Concentration	Atkinson 2016	Gabapentin (Mean 3265 mg)	1	108	38% (21/55)	11% (6/53)	RR 3.37 (95% Cl 1.48, 7.70)*	4
Anticonvulsants	Dry Mouth	Atkinson 2016	Gabapentin (Mean 3265 mg)	1	108	40% (22/55)	19% (10/53)	RR 2.12 (95% Cl 1.11, 4.04)*	5
Anticonvulsants	Fatigue	Atkinson 2016	Gabapentin (Mean 3265 mg)	1	108	49% (27/55)	28% (15/53)	RR 1.73 (1.05, 2.88)*	5
Anticonvulsants	Dizziness	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	43.6% (24/55)	26.4% (14/53)	RR 1.65 (95% Cl 0.96, 2.84)*	NSS
Anticonvulsants	GI-Related (Nausea, Vomiting, Constipation, Diarrhea)	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	36.4% (20/55)	45.3% (24/53)	RR 0.80 (95% Cl 0.51, 1.27)*	NSS
Anticonvulsants	Sexual Side Effects (Erectile Dysfunction, Decreased Sexual Desire)	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	20% (11/55)	7.5% (4/53)	RR 2.65 (95% Cl 0.90, 7.81)*	NSS
Anticonvulsants	Sleep Disturbances	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	50.9% (28/55)	39.6% (21/53)	RR 1.28 (95% Cl	NSS

								0.84 <i>,</i> 1.96)*	
Anticonvulsants	Weight Gain	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	10.9% (6/55)	1.9% (1/53)	RR 5.78 (95% Cl 0.72, 46.43)*	NSS
Anticonvulsants	Withdrawal Due to Adverse Events	Atkinson 2016	Gabapentin (Mean 3265 mg) Placebo	1	108	12.7% (7/55)	9.4% (5/53)	RR 1.35 (95% Cl 0.46, 3.99)*	NSS
Exercise	Adverse Events	Saper 2017a	Yoga Back Pain Help Book	1	320	7.1% (9/127)	3.1% (1/32)	RR 2.27 (95% Cl 0.30, 17.25)*	NSS
Exercise	Adverse Events	Saper 2017b	Physical Therapy Back Pain Help Book	1	320	10.9% (14/129)	0% (0/32)	RR 7.36 (95% Cl 0.45, 120.24)*	NSS
Exercise	Increased Back Pain	Saper 2017a	Yoga Back Pain Help Book	1	320	3.1% (4/127)	3.1% (1/32)	RR 1.01 (95% Cl 0.12, 8.71)*	NSS
Exercise	Increased Back Pain	Saper 2017b	Physical Therapy Back Pain Help Book	1	320	3.9% (5/129)	0% (0/32)	RR 2.79 (95% Cl 0.16, 49.24)*	NSS
Exercise	Increased Pain	Jensen 2012	Physiotherapy-delivered exercise Prescribed rest	1	100	6.1% (3/49)	9.8% (5/51)	RR 0.62 (95% Cl 0.16, 2.47)*	NSS
Exercise	Joint Pain	Saper 2017a	Yoga Back Pain Help Book	1	320	3.1% (4/127)	0% (0/32)	RR 2.32 (95% Cl 0.13, 42.03)*	NSS

Exercise	Joint Pain	Saper 2017b	Physical Therapy Back Pain Help Book	1	320	6.2% (8/129)	0% (0/32)	RR 4.32 (95% Cl 0.26, 72.87)*	NSS
Exercise	Mild Muscle Soreness	Brodsky 2019	Group Stretching Self-Care Book	1	69	11.8% (4/34)	8.6% (3/35)	RR 1.37 (95% Cl 0.33, 5.68)*	NSS
Exercise	Mild Adverse Events	Costa 2009	Physiotherapy-delivered motor control exercises Sham detuned shortwave diathermy/ultrasound	1	144	3.9% (3/77)	2.6% (2/77)	RR 1.50 (95% Cl 0.26, 8.73)*	NSS
Exercise	Serious Adverse Events	Saper 2017a	Yoga Back Pain Help Book	1	320	0.79% (1/127)	0% (0/32)	RR 0.77 (95% Cl 0.03, 18.56)*	NSS
Continentonoid	Accidental	Caratta 1007	Continentoneid Iniertiene	1	150	1.20/	1 20/	DD 1 02	NCC
Corticosteroid Injections	Dural Puncture	Carette 1997	Corticosteroid Injections (0,3,6 weeks if no marked improvement) Saline Injections (0,3,6 weeks)	1	158	1.3% 1/78	1.3% 1/80	RR 1.03 (95% CI 0.07, 16.11)	NSS
Corticosteroid Injections	Death	Nguyen 2017	Single Corticosteroid Injection Single Injection of Contrast	1	135	1.5% (1/67)	0% (0/68)	RR 3.04 (95% Cl 0.13, 73.43)	NSS
Corticosteroid Injections	Non-Specific Headache	Arden 2005	Corticosteroid Injections (0,3,6 weeks) Saline Injections (0,3,6 weeks)	1	228	3.3% (4/120)	3.7% (4/108)	RR 0.90 (95% Cl 0.23, 3.51)	NSS
Corticosteroid Injections	Postdural Puncture Headache and Nausea	Arden 2005	Corticosteroid Injections (0,3,6 weeks) Saline Injections (0,3,6 weeks)	1	228	1.7% (2/120)	1.9% (2/108)	RR 0.90 (95% Cl 0.13, 6.28)	NSS

Corticosteroid Injections	Serious Adverse Events	Nguyen 2017	Single Corticosteroid Injection Single Injection of Contrast	1	135	0% (0/67)	1.5% (1/68)	RR 0.34 (95% Cl 0.01, 8.16)	NSS
Corticosteroid Injections	Transient Headache	Carette 1997	Corticosteroid Injections (0,3,6 weeks if no marked improvement) Saline Injections (0,3,6 weeks)	1	158	26.9% (21/78)	20.0% (16/80)	RR 1.35 (95% Cl 0.76, 2.38)	NSS
Corticosteroid Injections	Vasovagal Response	Ghai 2015	Corticosteroid and Lidocaine Injection (Multiple if pain relief of <50% was deteriorated, spaced at least 15 days) Lidocaine Injection (Multiple if pain relief of <50% was deteriorated, spaced at least 15 days)	1	69	0% (0/35)	2.9% (1/34)	RR 0.32 (95% Cl 0.01, 7.69)	NSS
Opioids	Hot Flushes	Peloso 2004	 Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Placebo 	1	336	7% (11/167)	1% (1/169)	RR 11.13 (95% Cl 1.45, 85.26)	17
Opioids	Hyperhidrosis	Buynak 2010, Cristoph 2017, Peloso 2004, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol ER 200mg QD Placebo 	4	1874	9% (97/1140)	0.4% (3/734)	RR 9.36 (95% Cl 3.64, 24.07)	13

Opioids	Pruritus	Buynak 2010, Ruoff 2003	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	2	1283	11% (89/807)	2% (8/476)	RR 5.80 (95% Cl 2.82, 11.94)	11
Opioids	Vomiting	Buynak 2010, Cristoph 2017, Peloso 2004, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol ER 200mg QD Placebo 	4	2174	14% (208/1440)	2% (15/734)	RR 5.50 (95% Cl 3.25, 9.32)	9
Opioids	Somnolence	Buynak 2010, Cristoph 2017, Peloso 2004, Ruoff 2003	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	4	2256	16% (231/1485)	3% (21/771)	RR 5.20 (95% Cl 3.34, 8.08)	8
Opioids	Anorexia	Peloso 2004	 Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Placebo 	1	336	7% (11/167)	2% (3/169)	RR 3.71 (95% Cl 1.05, 13.06)	21
Opioids	Nausea	Buynak 2010, Cristoph 2017, Lee 2013, Peloso 2004,	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID 	6	2737	26% (454/1726)	7% (67/1011)	RR 3.62 (95% Cl 2.83, 4.63)	6

		Ruoff 2003, Uberall 2012	 Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 1-2tabs BID Tramadol ER 200mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 						
Opioids	Dry Mouth	Buynak 2010, Peloso 2004, Ruoff 2003, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tramadol ER 200mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	4	1855	7% (77/1090)	2% (16/765)	RR 3.24 (95% Cl 1.88, 5.61)	21
Opioids	Constipation	Buynak 2010, Cristoph 2017, Peloso 2004, Ruoff 2003, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol ER 200mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	5	2737	17% (276/1601)	5% (45/891)	RR 3.17 (95% Cl 2.32, 4.35)	9

Opioids	Dizziness	Buynak 2010, Cristoph 2017, Lee 2013, Peloso 2004, Ruoff 2003, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 1-2tabs BID Tramadol ER 200mg QD Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	6	2737	24% (409/1722)	8% (80/1007)	RR 2.77 (95% Cl 2.21, 3.47)	7
Opioids	Fatigue	Buynak 2010, Cristoph 2017, Ruoff 2003, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol ER 200mg QD Tramadol Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	4	2156	9% (136/1434)	3% (23/722)	RR 2.30 (95% Cl 1.46, 3.62)	16
Opioids	Headache	Buynak 2010, Cristoph 2017, Lee 2013, Peloso 2004, Ruoff 2003, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol/Acetaminopen ER 37.5/325mg 1-2tabs BID Tramadol ER 200mg QD 	6	2737	14% (244/1726)	10% (106/1011)	RR 1.35 (95% Cl 1.09, 1.67)	28

			 Tramadol/Acetaminopen ER 37.5/325mg 3-8 tabs per day Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 						
Opioids	Abdominal Discomfort	Uberall 2012	Tramadol ER 200mg QDPlacebo	1	236	4.3% (5/116)	5.0% (6/120)	RR 0.86 (95% Cl 0.27, 2.75)	NSS
Opioids	Diarrhea	Buynak 2010	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Placebo 	1	965	4% (27/646)	7% (23/319)	RR 0.56 (95% Cl 0.25, 1.23)	NSS
Opioids	Dyspepsia	Buynak 2010, Lee 2013, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tramadol/Acetaminopen ER 37.5/325mg 1-2tabs BID Tramadol ER 200mg QD Placebo 	3	1146	4% (38/887)	4% (21/559)	RR 1.22 (95% Cl 0.71, 2.08)	NSS
Opioids	Hepatic Enzyme Increased	Uberall 2012	Tramadol ER 200mg QDPlacebo	1	236	0% (0/115)	4.2% (5/120)	RR 0.09 (95% Cl 0.01, 1.68)	NSS
Opioids	Insomnia	Buynak 2010	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Placebo 	1	965	5.9% (38/646)	2.8% (9/319)	RR 1.98 (95% Cl 0.86, 4.53)	NSS
Opioids	Serious Adverse Event	Buynak 2010, Cristoph 2017, Uberall 2012	 Oxycodone CR 20-50mg BID Tapentadol ER 100- 250mg BID Tapentadol PR 200mg BID Cebranopadol 200- 600mg QD Tramadol ER 200mg QD Placebo 	3	2166	2.4% (30/1273)	0.88% (5/565)	RR 2.10 (95% Cl 0.81, 5.48)	NSS

Opioids	Sinusitis	Ruoff 2003	 Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	1	318	5.0% (8/161)	3.2% (5/157)	RR 1.56 (95% Cl 0.52, 4.67)	NSS
Opioids	Upper Respiratory Tract Infection	Ruoff 2003	 Tramadol/Acetaminopen ER 37.5/325mg 1-8 tabs per day Placebo 	1	318	5.6% (9/161)	7.6% (12/157)	RR 0.73 (95% Cl 0.32, 1.69)	NSS
Oral NSAIDs	≥1 Adverse Event	Coats 2004	Valdecoxib 40 mg daily Placebo	1	293	35% (52/148)	24% (35/145)	RR 1.46 (95% Cl 1.01, 2.09)*	10
Oral NSAIDs	Any adverse event	Katz 2003	Rofecoxib 25 mg Placebo	1	461	48.1% (112/233)	40.8% (93/228)	RR 1.78 (95% Cl 0.96, 1.45)*	NSS
Oral NSAIDs	Any adverse event	Katz 2003	Rofecoxib 50 mg Placebo	1	457	46.3% (106/229)	40.8% (93/228)	RR 1.13 (95% Cl 0.92, 1.40)*	NSS
Oral NSAIDs	Any adverse event	Katz 2011	Naproxen 1000 mg daily Placebo	1	129	61.4% (54/88)	65.9% (27/41)	RR 0.93 (95% Cl 0.71, 1.23)*	NSS
Oral NSAIDs	Arthralgia	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	1.4% (4/295)	1.7% (4/230)	RR 0.78 (95% Cl 0.20, 3.08)	NSS
Oral NSAIDs	Congestive Heart Failure	Katz 2003	Rofecoxib 25 mg Placebo	1	461	0.4% (1/233)	0% (0/228)	RR 2.94 (95% Cl 0.12, 71.70)	NSS
Oral NSAIDs	Diarrhea	Katz 2003	Rofecoxib 25 mg Placebo	1	461	7.3% (17/233)	3.5% (8/228)	RR 2.08 (95% Cl 0.92, 4.72)*	NSS
Oral NSAIDs	Diarrhea	Katz 2003	Rofecoxib 50 mg Placebo	1	457	4.8% (11/229)	3.5% (8/228)	RR 1.37 (95% Cl 0.56, 3.34)	NSS

Oral NSAIDs	Dizziness	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	1.4% (4/295)	3.0% (7/230)	RR 0.45 (95% Cl 0.13, 1.50)	NSS
Oral NSAIDs	Edema	Katz 2003a Katz 2003b Kivitz 2013	Oral NSAIDs Placebo	2	1215	2.2% (17/757)	0.87% (4/458)	RR 2.12 (95% Cl 0.68, 6.65)	NSS
Oral NSAIDs	Headache	Katz 2003a Katz 2003b Kivitz 2013	Oral NSAIDs Placebo	2	1215	5.9% (45/757)	7.0% (32/458)	RR 0.78 (95% Cl 0.50, 1.21)	NSS
Oral NSAIDs	Hyperesthesia	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	0% (0/295)	0.87% (2/230)	RR 0.16 (95% Cl 0.01, 3.24)	NSS
Oral NSAIDs	Hypertension	Katz 2003	Rofecoxib 25 mg Placebo	1	461	0.86% (2/233)	0.88% (2/228)	RR 0.98 (95% Cl 0.14, 6.89)	NSS
Oral NSAIDs	Hypertension	Katz 2003	Rofecoxib 50 mg Placebo	1	457	2.2% (5/229)	0.88% (2/228)	RR 2.49 (95% Cl 0.49, 12.70)	NSS
Oral NSAIDs	Hypoesthesia	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	2.7% (8/295)	2.6% (6/230)	RR 1.04 (95% Cl 0.37, 2.95)	NSS
Oral NSAIDs	MSK Pain	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	1.0% (3/295)	3.0% (7/230)	RR 0.33 (95% Cl 0.09, 1.28)	NSS
Oral NSAIDs	Muscle Spasms	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	0.68% (2/295)	0.87% (2/230)	RR 0.78 (95% Cl 0.11, 5.49)	NSS
Oral NSAIDs	Myocardial Infarction	Katz 2003	Rofecoxib 50 mg Placebo	1	457	0.4% (1/229)	0% (0/228)	RR 2.99 (95% Cl 0.12, 72.94)	NSS
Oral NSAIDs	Nasopharyngitis	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	3.1% (9/295)	0.87% (2/230)	RR 3.51 (95% Cl 0.77, 16.08)	NSS

Oral NSAIDs	Nausea	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	3.1% (9/295)	0.87% (2/230)	RR 3.51 (95% Cl 0.77, 16.08)	NSS
Oral NSAIDs	Pain in extremity	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	0.68% (2/295)	1.7% (4/230)	RR 0.39 (95% Cl 0.07, 2.11)	NSS
Oral NSAIDs	Paresthesia	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	1.7% (5/295)	2.2% (5/230)	RR 0.78 (95% Cl 0.23, 2.66)	NSS
Oral NSAIDs	Serious Adverse Events	Coats 2004 Katz 2011	Oral NSAIDs Placebo	2	422	3.0% (7/236)	2.7% (5/186)	RR 1.11 (95% Cl 0.36, 3.43)	NSS
Oral NSAIDs	Treatment- related adverse events	Katz 2011	Naproxen 1000 mg daily Placebo	1	129	18.2% (16/88)	22.0% (9/41)	RR 0.83 (95% Cl 0.40, 1.71)*	NSS
Oral NSAIDs	Upper Respiratory Infection	Katz 2003a Katz 2003b Kivitz 2013	Oral NSAIDs Placebo	2	1215	4.5% (34/757)	4.4% (20/458)	RR 1.01 (95% Cl 0.59, 1.75)	NSS
Oral NSAIDs	Urinary Tract Infection	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	2.0% (6/295)	3.5% (8/230)	RR 0.58 (95% Cl 0.21, 1.66)	NSS
Oral NSAIDs	Withdrawal due to Adverse Events	Coats 2004 Katz 2003a Katz 2003b Katz 2011 Kivitz 2013	Oral NSAIDs Placebo	4	1637	3.7% (37/993)	3.1% (20/644)	RR 1.36 (95% Cl 0.53, 3.51)	NSS
Oral NSAIDs	≥1 adverse event	Kivitz 2013	Naproxen 1000 mg daily Placebo	1	525	48.1% (142/295)	52.2% (120/230)	RR 0.92 (95% Cl 0.78, 1.10)	NSS
Rubefacients	Heat Sensation	Chrubasik 2010, Keitel 2001	Capsaicin 0.05% Cream applied 3x/day Placebo Cream	2	292	78.9% (127/145)	32.4% (60/147)	RR 2.10 (95% Cl 1.73, 2.56)	3

			Capsaicin Plaster Placebo Plaster						
Rubefacients	Mild or Moderate Local Erythema	Frerick 2003	Capsaicin Plaster applied once daily for 4- 8 hours Placebo Plaster	1	301	67.6% (100/148)	48.4% (75/153)	RR 1.38 (95% Cl 1.13, 1.68)	6
Rubefacients	Local Mild Inflammation	Frerick 2003	Capsaicin Plaster applied once daily for 4- 8 hours Placebo Plaster	1	301	18.9% (28/148)	11.8% (18/153)	RR 1.61 (95% Cl 0.93, 2.78)	NSS
Rubefacients	Pruritus	Chrubasik 2010, Keitel 2001	Capsaicin 0.05% Cream applied 3x/day Placebo Cream Capsaicin Plaster Placebo Plaster	2	292	29.0% (42/145)	17.7% (26/147)	RR 1.86 (95% Cl 0.78, 4.45)	NSS
SNRI (Duloxetine)	Dizziness	Konno 2016, Skljarevski 2010	Duloxetine 60mg/day Placebo	2	859	5.3% (23/430)	0.93% (4/429)	RR 5.55 (95% Cl 1.92, 16.02)	23
SNRI (Duloxetine)	Nausea	Konno 2016, Skljarevski 2010	Duloxetine 60mg/day Placebo	2	859	13.3% (57/430)	2.8% (12/429)	RR 4.65 (95% Cl 2.53, 8.57)	10
SNRI (Duloxetine)	Somnolence	Konno 2016	Duloxetine 60mg/day Placebo	1	458	19.4% (45/232)	7.1% (16/226)	RR 2.74 (95% Cl 1.60, 4.70)	9
SNRI (Duloxetine)	Withdrawal due to AE	Sklijarevski 2010	Duloxetine 60mg/day Placebo	1	458	18.5% (53/287)	8.5% (10/117)	RR 2.16 (95% Cl 1.14, 4.10)	11
SNRI (Duloxetine)	At Least one Treatment Emergent Adverse Event	Sklijarevski 2010a	Duloxetine 60- 120mg/day Placebo	1	236	56.5% (65/115)	47.9% (58/121)	RR 1.41 (95% Cl 0.85, 2.36)	NSS

SNRI (Duloxetine)	At Least one Serious Adverse Event	Sklijarevski 2009, Sklijarevski 2010a	Duloxetine 60- 120mg/day Placebo	2	640	2.2% (9/402)	1.7% (4/238)	RR 1.18 (95% Cl 0.35, 3.98)	NSS
SNRI (Duloxetine)	Constipation	Konno 2016, Skljarevski 2010	Duloxetine 60mg/day Placebo	2	859	8.1% (35/430)	3.0% (13/429)	RR 2.48 (95% Cl 0.66, 9.31)	NSS
SNRI (Duloxetine)	Contusion	Konno 2016	Duloxetine 60mg/day Placebo	1	458	6.9% (16/232)	3.1% (7/226)	RR 2.23 (95% Cl 0.93, 5.31)	NSS
SNRI (Duloxetine)	Dry Mouth	Konno 2016, Skljarevski 2010	Duloxetine 60mg/day Placebo	2	859	6.0% (26/430)	1.0% (4/429)	RR 6.76 (95% Cl 0.68, 67.37)	NSS
SNRI (Duloxetine)	Nasopharyngitis	Konno 2016	Duloxetine 60mg/day Placebo	1	458	11.2% (26/232)	17.3% (39/226)	RR 0.65 (95% Cl 0.41, 1.03)	NSS
SNRI (Duloxetine)	Serious Adverse Events	Sklijarevski 2010	Duloxetine 60mg/day Placebo	1	458	1.7% (5/287)	2.6% (3/117)	RR 0.68 (95% Cl 0.17, 2.80)	NSS
Spinal Manipulation	Adverse Events	Goertz 2017	Spinal Manipulation + Medical Care Medical Care	1	83	50.0% (22/44)	5.1% (2/39)	RR 9.75 (95% Cl 2.45, 38.83)	3
Spinal Manipulation	Adverse Events	Bond 2020	Spinal Manipulation Sham Manipulation	1	29	7.1% (1/14)	0% (0/15)	RR 3.2 (95% Cl 0.14, 72.63)	NSS
Spinal Manipulation	Adverse Events	Licciardone 2013	Spinal Manipulation Sham Manipulation	1	455	7.0% (16/230)	4.9% (11/225)	RR 1.42 (95% Cl 0.68, 3.00)	NSS
Spinal Manipulation	Local, mild joint pain	Bond 2020	Spinal Manipulation Sham Manipulation	1	29	7.1% (1/14)	0% (0/15)	RR 3.2 (95% Cl 0.14, 72.63)	NSS

Spinal Manipulation	Serious Adverse Events	Licciardone 2013	Spinal Manipulation Sham Manipulation	1	455	2.6% (6/230)	1.3% (3/225)	RR 1.96 (95% Cl 0.50, 7.73)	NSS
Topical NSAIDs	Adverse Events	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	25.9% (22/85)	50% (21/42)	RR 0.52 (95% Cl 0.32, 0.83)*	5
Topical NSAIDs	Application Site Rash	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	3.5% (3/85)	9.5% (4/42)	RR 0.37 (95% Cl 0.09, 1.58)*	NSS
Topical NSAIDs	Arthalgia	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	0% (0/85)	4.8% (2/42)	RR 0.10 (95 % Cl 0.00, 2.04)*	NSS
Topical NSAIDs	Dizziness	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	2.4% (2/85)	4.8% (2/42)	RR 0.49 (95% Cl 0.07, 3.39)*	NSS
Topical NSAIDs	Erythema at Application Site	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	7.1% (6/85)	9.5% (4/42)	RR 0.74 (95% Cl 0.22, 2.49)*	NSS
Topical NSAIDs	Headache	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	3.5% (3/85)	9.5% (4/42)	RR 0.37 (95% Cl 0.09, 1.58)*	NSS
Topical NSAIDs	Insomnia	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	0% (0/85)	4.8% (2/42)	RR 0.10 (95% Cl 0.00, 2.04)*	NSS
Topical NSAIDs	Irritation at Application Site	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	7.1% (6/85)	7.1% (3/42)	RR 0.99 (95% Cl 0.26, 3.76)*	NSS

Topical NSAIDs	Joint Stiffness	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	0% (0/85)	2.4% (1/42)	RR 0.17 (95% Cl 0.01, 4.01)*	NSS
Topical NSAIDs	Neck Pain	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	0% (0/85)	2.4% (1/42)	RR 0.17 (95% Cl 0.01, 4.01)*	NSS
Topical NSAIDs	Pain in Extremities	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12 hours/day Placebo	1	127	0% (0/85)	2.4% (1/42)	RR 0.17 (95% Cl 0.01, 4.01)*	NSS
Topical NSAIDs	Papular Rash	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12 hours/day Placebo	1	127	0% (0/85)	2.4% (1/42)	RR 0.17 (95% Cl 0.01, 4.01)*	NSS
Topical NSAIDs	Paraesthesia at Application Site	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	0% (0/85)	2.4% (1/42)	RR 0.17 (95% Cl 0.01, 4.01)*	NSS
Topical NSAIDs	Pruritus at Application Site	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	7.1% (6/85)	14.3% (6/42)	RR 0.49 (95% Cl 0.17, 1.44)*	NSS
Topical NSAIDs	Stomach Discomfort	Song 2008	Flubiprofen Tape (63 mg/day); Worn 12-24 hours/day Placebo	1	127	1.2% (1/85)	4.8% (2/42)	RR 0.25 (95% Cl 0.02, 2.65)*	NSS

RR: Risk Ratio; CI: Confidence Interval; RR: Risk Ratio; NNH: Number Needed to Harm; NSS: Not statistically significant; ER: Extended Release; CR: Controlled Release; QD: Once Daily; BID: Twice daily; mg: Milligrams

Oral NSAIDs

	NSAII	Ds	Conti	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Coats 2004	3	148	1	145	12.6%	2.94 [0.31, 27.93]	
Katz 2003a	11	233	1	114	14.6%	5.38 [0.70, 41.18]	
Katz 2003b	10	229	2	114	21.0%	2.49 [0.55, 11.17]	
Katz 2011	3	88	2	41	17.7%	0.70 [0.12, 4.02]	
Kivitz 2013	10	295	14	230	34.1%	0.56 [0.25, 1.23]	
Total (95% CI)		993		644	100.0%	1.36 [0.53, 3.51]	-
Total events	37		20				
Heterogeneity: Tau ² =	= 0.52; Cł	1i ² = 7.	48, df =	4 (P =	0.11); I ² =	= 47%	
Test for overall effect	: Z = 0.64	4 (P = 0).52)				0.01 0.1 1 10 100 Favours control Favours NSAIDs

Figure 12.1 Oral NSAIDs versus placebo; Withdrawals due to Adverse Events

Figure 12.2 Oral NSAIDs versus placebo; Serious Adverse Events

	NSAI	Ds	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M–H, Random, 95% CI
Coats 2004	5	148	5	145	86.0%	0.98 [0.29, 3.31]	
Katz 2011	2	88	0	41	14.0%	2.36 [0.12, 48.07]	
Total (95% CI)		236		186	100.0%	1.11 [0.36, 3.43]	
Total events	7		5				
Heterogeneity: Tau ² =	= 0.00; C	$hi^2 = 0.$	28, df =	1 (P =	0.59); I ² =	= 0%	
Test for overall effect	: Z = 0.1	8 (P = 0	0.86)				0.01 0.1 1 10 100 Favours control Favours NSAIDs

Figure 12.3 Oral NSAIDs versus placebo; Adverse Event: Edema

	NSAI	Ds	Cont	rol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Katz 2003a	4	233	1	114	27.5%	1.96 [0.22, 17.31]	
Katz 2003b	10	229	1	114	31.3%	4.98 [0.65, 38.41]	
Kivitz 2013	3	295	2	230	41.2%	1.17 [0.20, 6.94]	
Total (95% CI)		757		458	100.0%	2.12 [0.68, 6.65]	
Total events	17		4				
Heterogeneity: Tau ² = Test for overall effect				2 (P =	0.56); I ²	= 0%	0.01 0.1 1 10 100 Favours control Favours NSAIDs

Figure 12.4 Oral NSAIDs versus placebo; Adverse Event: Headache

	NSAII	Ds	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Katz 2003a	19	233	12	114	40.3%	0.77 [0.39, 1.54]	-
Katz 2003b	15	229	11	114	34.3%	0.68 [0.32, 1.43]	- e +
Kivitz 2013	11	295	9	230	25.5%	0.95 [0.40, 2.26]	+
Total (95% CI)		757		458	100.0%	0.78 [0.50, 1.21]	•
Total events	45		32				
Heterogeneity: Tau ²	= 0.00; Cł	$hi^2 = 0.$	34, df =	2 (P =	0.84); I ² =	= 0%	0.01 0.1 1 10 100
Test for overall effect	t: $Z = 1.11$	1 (P = 0)).27)				Favours control Favours NSAIDs

Figure 12.5 Oral NSAIDs versus placebo; Adverse Event: Upper Respiratory Infection

	NSAI	Ds	Conti	rol		Risk Ratio		Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Random, 95% CI	
Katz 2003a	9	233	5	114	26.1%	0.88 [0.30, 2.57]		_	
Katz 2003b	13	229	5	114	29.5%	1.29 [0.47, 3.54]			
Kivitz 2013	12	295	10	230	44.3%	0.94 [0.41, 2.13]			
Total (95% CI)		757		458	100.0%	1.01 [0.59, 1.75]		•	
Total events	34		20						
Heterogeneity: Tau ² =	= 0.00; Cl	$ni^2 = 0.$	33, df =	2 (P =	0.85); I ² =	= 0%	0.01	0,1 1 10	100
Test for overall effect	: Z = 0.0	5 (P = 0).96)					Favours control Favours NSAIDs	

Rubefacients

Figure 13.1 Rubefacients versus placebo; Adverse Event: Heat Sensation

	Rubefac	ients	Place	oo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	I M-H, Random, 95% CI
Chrubasik 2010	56	71	23	71	30.3%	2.43 [1.70, 3.48]	
Keitel 2001	71	74	37	76	69.7%	1.97 [1.56, 2.49]	
Total (95% CI)		145		147	100.0%	2.10 [1.73, 2.56]	•
Total events	127		60				
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.99, 0	df = 1 (P =	= 0.32)	I ² = 0%		0.01 0.1 1 10 100
Test for overall effect:	Z = 7.40 (F	o < 0.000	001)				Favours [Rubefacients] Favours [Placebo]

Figure 13.2 Rubefacients versus placebo; Adverse Event: Pruritus

	Rubefac	ients	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
Chrubasik 2010	8	71	2	71	24.3%	4.00 [0.88, 18.18]	
Keitel 2001	34	74	24	76	75.7%	1.45 [0.96, 2.20]	
Total (95% CI)		145		147	100.0%	1.86 [0.78, 4.45]	
Total events	42		26				
Heterogeneity: Tau ² =	0.22; Chi ²	= 1.68, d	df = 1 (P =	= 0.20);	l² = 40%		0.01 0.1 1 10 100
Test for overall effect:	Z = 1.40 (F	P = 0.16))				Favours [Rubefacients] Favours [Placebo]

Opioids

Figure 14.1 Opioids versus placebo; Withdrawals due to Adverse Events

	Opioio	ds	Placel	oo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	104	328	7	159	15.4%	7.20 [3.43, 15.12]	_ _ _
Buynak 2010 (Tapentadol)	53	318	7	160	14.5%	3.81 [1.77, 8.19]	
Cristoph 2017 (Cebranopadol)	156	385	2	63	4.5%	12.76 [3.25, 50.18]	
Cristoph 2017 (Tapentadol)	33	126	2	63	4.4%	8.25 [2.04, 33.28]	
Lee 2013	24	125	6	120	11.5%	3.84 [1.63, 9.06]	
Peloso 2004	47	167	13	169	25.6%	3.66 [2.06, 6.51]	
Ruoff 2003	30	161	9	157	16.8%	3.25 [1.60, 6.62]	_ _
Uberall 2012	14	116	4	120	7.3%	3.62 [1.23, 10.68]	
Total (95% CI)		1726		1011	100.0%	4.41 [3.30, 5.91]	•
Total events	461		50				
Heterogeneity: Tau ² = 0.00; Chi ²	= 6.92, df	= 7 (P	= 0.44); I	² = 0%			
Test for overall effect: Z = 9.99 (I	⊃ < 0.0000	01)					0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.2 Opioids versus placebo; Serious Adverse Events

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	11	328	1	159	22.1%	5.33 [0.69, 40.94]	
Buynak 2010 (Tapentadol)	7	318	2	160	37.7%	1.76 [0.37, 8.38]	
Cristoph 2017 (Cebranopadol)	9	385	1	63	21.9%	1.47 [0.19, 11.43]	
Cristoph 2017 (Tapentadol)	3	126	1	63	18.3%	1.50 [0.16, 14.13]	
Uberall 2012	0	116	0	120		Not estimable	
Total (95% CI)		1273		565	100.0%	2.10 [0.81, 5.48]	
Total events	30		5				
Heterogeneity: Tau ² = 0.00; Chi ²	= 1.10, di	= 3 (P	= 0.78); I	² = 0%			
Test for overall effect: Z = 1.52 (P = 0.13)						0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.3 Opioids versus placebo; Adverse Event: Constipation

	Opioi	ds	Placel	00		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	dom, 95% Cl	
Buynak 2010 (Oxycodone)	88	328	8	159	20.4%	5.33 [2.65, 10.72]				
Buynak 2010 (Tapentadol)	44	318	8	160	18.7%	2.77 [1.33, 5.74]				
Cristoph 2017 (Cebranopadol)	62	385	2	63	5.2%	5.07 [1.27, 20.22]				
Cristoph 2017 (Tapentadol)	22	126	3	63	7.3%	3.67 [1.14, 11.79]				
Peloso 2004	37	167	13	169	28.1%	2.88 [1.59, 5.22]				
Ruoff 2003	18	161	8	157	15.4%	2.19 [0.98, 4.90]				
Uberall 2012	5	116	3	120	5.0%	1.72 [0.42, 7.05]				
Total (95% CI)		1601		891	100.0%	3.17 [2.32, 4.35]			•	
Total events	276		45							
Heterogeneity: Tau ² = 0.00; Chi ²	= 4.56, d	f = 6 (P	= 0.60); I	² = 0%					1 10	4.04
Test for overall effect: Z = 7.18 (P < 0.000	01)					0.01	0.1 Favours [Opioids]	Favours [Placebo]	10

Figure 14.4 Opioids versus placebo; Adverse Event: Diarrhea




Figure 14.5 Opioids versus placebo; Adverse Event: Dizziness




Figure 14.6 Opioids versus placebo; Adverse Event: Dry Mouth

	Opioi	ds	Place	bo		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		M-H, Rand	dom, 95% Cl	
Buynak 2010 (Oxycodone)	12	328	3	159	18.9%	1.94 [0.56, 6.77]				
Buynak 2010 (Tapentadol)	26	318	4	160	27.4%	3.27 [1.16, 9.21]				
Peloso 2004	24	167	6	169	38.6%	4.05 [1.70, 9.65]				
Ruoff 2003	13	161	1	157	7.3%	12.68 [1.68, 95.76]				
Uberall 2012	2	116	2	120	7.9%	1.03 [0.15, 7.22]				
Total (95% CI)		1090		765	100.0%	3.24 [1.88, 5.61]			•	
Total events	77		16							
Heterogeneity: Tau ² = 0.01;	Chi ² = 4.08	5, df = 4	(P = 0.4	0); I ² =	1%					100
Test for overall effect: Z = 4.	21 (P < 0.0	0001)					0.01	0.1 Favours [Opioids]	1 10 Favours [Placebo]	

Figure 14.7 Opioids versus placebo; Adverse Event: Dyspepsia

	Opioi	ds	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Buynak 2010 (Oxycodone)	6	328	4	159	18.2%	0.73 [0.21, 2.54]	
Buynak 2010 (Tapentadol)	16	318	4	160	24.5%	2.01 [0.68, 5.92]	
Lee 2013	13	125	12	120	51.6%	1.04 [0.49, 2.19]	
Uberall 2012	3	116	1	120	5.6%	3.10 [0.33, 29.41]	
Total (95% CI)		887		559	100.0%	1.22 [0.71, 2.08]	•
Total events	38		21				
Heterogeneity: Tau ² = 0.00; 0	Chi² = 2.35	5, df = 3	B (P = 0.5	0); I ² =	0%		
Test for overall effect: Z = 0.7	2 (P = 0.4	47)					0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.8 Opioids versus placebo; Adverse Event: Fatigue

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	CI M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	24	328	6	159	26.9%	1.94 [0.81, 4.65]	
Buynak 2010 (Tapentadol)	21	318	7	160	29.6%	1.51 [0.66, 3.48]	│ ┼ ∎──
Cristoph 2017 (Cebranopadol)	55	385	1	63	5.4%	9.00 [1.27, 63.87]	· · · · · · · · · · · · · · · · · · ·
Cristoph 2017 (Tapentadol)	18	126	2	63	10.1%	4.50 [1.08, 18.79]	
Ruoff 2003	11	161	4	157	16.3%	2.68 [0.87, 8.24]	
Uberall 2012	7	116	3	120	11.7%	2.41 [0.64, 9.11]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		1434		722	100.0%	2.30 [1.46, 3.62]	◆
Total events	136		23				
Heterogeneity: Tau ² = 0.00; Chi ²	= 4.21, di	= 5 (P	= 0.52);	² = 0%			0.01 0.1 1 10 100
Test for overall effect: Z = 3.60 (P = 0.0003	3)					Favours [Opioids] Favours [Placebo]

Figure 14.9 Opioids versus placebo; Adverse Event: Headache

	Opioi	ds	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	I M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	55	328	22	159	21.9%	1.21 [0.77, 1.91]	
Buynak 2010 (Tapentadol)	63	318	22	160	22.9%	1.44 [0.92, 2.25]	+
Cristoph 2017 (Cebranopadol)	40	385	5	63	5.8%	1.31 [0.54, 3.19]	
Cristoph 2017 (Tapentadol)	10	126	6	63	4.9%	0.83 [0.32, 2.19]	
Lee 2013	11	125	6	120	4.9%	1.76 [0.67, 4.61]	+
Peloso 2004	47	167	37	169	32.7%	1.29 [0.88, 1.87]	+=-
Ruoff 2003	14	161	6	157	5.3%	2.28 [0.90, 5.77]	
Uberall 2012	4	116	2	120	1.6%	2.07 [0.39, 11.08]	
Total (95% CI)		1726		1011	100.0%	1.35 [1.09, 1.67]	◆
Total events	244		106				
Heterogeneity: Tau ² = 0.00; Chi ²	= 3.08, df	= 7 (P	= 0.88); I	² = 0%			
Test for overall effect: Z = 2.73 (F	P = 0.006)		,				0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.10 Opioids versus placebo; Adverse Event: Hyperhydrosis

	Opioi	ds	Place	bo		Risk Ratio		Risk R	atio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Rando	m, 95% Cl	
Buynak 2010 (Oxycodone)	17	328	0	159	11.3%	17.02 [1.03, 281.25]		-		
Buynak 2010 (Tapentadol)	12	318	0	160	11.2%	12.62 [0.75, 211.76]		+	-	
Cristoph 2017 (Cebranopadol)	38	385	1	63	23.1%	6.22 [0.87, 44.48]		+	-	_
Cristoph 2017 (Tapentadol)	12	126	1	63	21.9%	6.00 [0.80, 45.11]		+	-	_
Peloso 2004	14	167	1	169	21.9%	14.17 [1.88, 106.53]				
Uberall 2012	4	116	0	120	10.5%	9.31 [0.51, 170.97]				
Total (95% CI)		1440		734	100.0%	9.36 [3.64, 24.07]				
Total events	97		3							
Heterogeneity: Tau ² = 0.00; Chi ²	= 0.74, di	= 5 (P	= 0.98); I	² = 0%			0.01	01 1	10	100
Test for overall effect: Z = 4.64 (P < 0.000	01)					0.01		10 Favours [Placebo]	100

Figure 14.11 Opioids versus placebo; Adverse Event: Insomnia

	Opioi	ds	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	25	328	4	159	49.1%	3.03 [1.07, 8.56]	
Buynak 2010 (Tapentadol)	13	318	5	160	50.9%	1.31 [0.47, 3.61]	
Total (95% CI)		646		319	100.0%	1.98 [0.86, 4.53]	
Total events	38		9				
Heterogeneity: Tau ² = 0.08; 0	Chi² = 1.3 ⁻	l, df = 1	(P = 0.2	5); I² =	24%		0.01 0.1 1 10 100
Test for overall effect: Z = 1.6	61 (P = 0.1	11)					Favours [Insomnia] Favours [Placebo]

Figure 14.12 Opioids versus placebo; Adverse Event: Nausea

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Buynak 2010 (Oxycodone)	113	328	15	159	23.9%	3.65 [2.21, 6.05]	
Buynak 2010 (Tapentadol)	64	318	14	160	20.4%	2.30 [1.33, 3.97]	_ _ _
Cristoph 2017 (Cebranopadol)	113	385	4	63	6.6%	4.62 [1.77, 12.08]	
Cristoph 2017 (Tapentadol)	33	126	4	63	6.2%	4.13 [1.53, 11.13]	
Lee 2013	46	125	12	120	17.8%	3.68 [2.05, 6.60]	
Peloso 2004	42	167	10	169	14.1%	4.25 [2.21, 8.19]	
Ruoff 2003	21	161	5	157	6.7%	4.10 [1.58, 10.59]	
Uberall 2012	22	116	3	120	4.4%	7.59 [2.33, 24.66]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)		1726		1011	100.0%	3.62 [2.83, 4.63]	•
Total events	454		67				
Heterogeneity: Tau ² = 0.00; Chi ²	= 4.81, df	= 7 (P	= 0.68); I	² = 0%			
Test for overall effect: Z = 10.23	(P < 0.000	001)					0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.13 Opioids versus placebo; Adverse Event: Pruritis

	Opioi	ds	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Buynak 2010 (Oxycodone)	55	328	3	159	39.6%	8.89 [2.82, 27.97]	_
Buynak 2010 (Tapentadol)	23	318	3	160	36.9%	3.86 [1.18, 12.65]	_
Ruoff 2003	11	161	2	157	23.5%	5.36 [1.21, 23.81]	
Total (95% CI)		807		476	100.0%	5.80 [2.82, 11.94]	
Total events	89		8				
Heterogeneity: Tau ² = 0.00;	Chi² = 1.03	3, df = 2	2 (P = 0.6	0); l² =	0%		
Test for overall effect: Z = 4.	77 (P < 0.0	00001)					0.01 0.1 1 10 100 Favours [Opioids] Favours [Placebo]

Figure 14.14 Opioids versus placebo; Adverse Event: Somnolence

	Opioi	ds	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	I M-H, Random, 95% CI
Buynak 2010 (Oxycodone)	53	328	4	159	19.5%	6.42 [2.37, 17.43]	
Buynak 2010 (Tapentadol)	42	318	4	160	19.2%	5.28 [1.93, 14.47]	
Cristoph 2017 (Cebranopadol)	70	385	3	63	15.4%	3.82 [1.24, 11.75]	
Cristoph 2017 (Tapentadol)	18	126	3	63	13.9%	3.00 [0.92, 9.80]	
Peloso 2004	28	167	5	169	22.6%	5.67 [2.24, 14.32]	
Ruoff 2003	20	161	2	157	9.4%	9.75 [2.32, 41.03]	
Total (95% CI)		1485		771	100.0%	5.20 [3.34, 8.08]	•
Total events	231		21				
Heterogeneity: Tau ² = 0.00; Chi ²	= 2.07, df	= 5 (P	= 0.84); I	² = 0%			0.01 0.1 1 10 100
Test for overall effect: Z = 7.32 (P < 0.0000	01)					Favours [Opioids] Favours [Placebo]

Figure 14.15 Opioids versus placebo; Adverse Event: Vomiting

	Opioi	ds	Placel	oo		Risk Ratio		Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C		M-H, Rand	dom, 95% Cl	
Buynak 2010 (Oxycodone)	63	328	2	159	14.3%	15.27 [3.78, 61.61]				
Buynak 2010 (Tapentadol)	29	318	3	160	20.2%	4.86 [1.50, 15.72]				
Cristoph 2017 (Cebranopadol)	69	385	2	63	14.6%	5.65 [1.42, 22.45]				
Cristoph 2017 (Tapentadol)	15	126	3	63	19.2%	2.50 [0.75, 8.32]		-		
Peloso 2004	19	167	4	169	24.9%	4.81 [1.67, 13.83]			_	
Uberall 2012	13	116	1	120	6.8%	13.45 [1.79, 101.16]				
Total (95% CI)		1440		734	100.0%	5.50 [3.25, 9.32]			•	
Total events	208		15							
Heterogeneity: Tau ² = 0.00; Chi ²	= 4.89, di	f = 5 (P	= 0.43); I	² = 0%				0.1	1 10	400
Test for overall effect: Z = 6.34 (P < 0.000	01)					0.01	0.1 Favours [Opioids]	1 10 Favours [Placebo]	100

SNRI (Duloxetine)

Figure 15.1 SNRI (Duloxetine) versus placebo; Withdrawals due to Adverse Events

	Duloxetine 60n	ng/day	Placel	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Sklijarevski 2009 (Duloxetine 120mg/day)	27	112	3	39	32.7%	3.13 [1.01, 9.76]	
Sklijarevski 2009 (Duloxetine 20mg/day)	9	59	3	39	27.3%	1.98 [0.57, 6.87]	
Sklijarevski 2009 (Duloxetine 60mg/day)	17	116	4	39	40.0%	1.43 [0.51, 3.99]	
Total (95% CI)		287		117	100.0%	2.02 [1.06, 3.87]	
Total events	53		10				
Heterogeneity: Tau ² = 0.00; Chi ² = 1.03, df =	= 2 (P = 0.60); l ² =	0%					
Test for overall effect: Z = 2.12 (P = 0.03)							0.1 0.2 0.5 1 2 5 10 Favours SNRI Favours Placebo

Figure 15.2 SNRI (Duloxetine) versus placebo; Serious Adverse Events

	Duloxe	tine	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
Sklijarevski 2009 (Duloxetine 120mg/day)	3	112	1	39	29.6%	1.04 [0.11, 9.75]	+
Sklijarevski 2009 (Duloxetine 20mg/day)	1	59	1	39	19.6%	0.66 [0.04, 10.26]	
Sklijarevski 2009 (Duloxetine 60mg/day)	1	116	1	39	19.6%	0.34 [0.02, 5.25]	
Skljarevski 2010a	4	115	1	121	31.2%	4.21 [0.48, 37.10]	
Total (95% CI)		402		238	100.0%	1.18 [0.35, 3.98]	
Total events	9		4				
Heterogeneity: Tau ² = 0.00; Chi ² = 2.34, df =	= 3 (P = 0.	50); l² =	= 0%			⊢	01 0.1 1 10 100
Test for overall effect: Z = 0.27 (P = 0.79)						0.0	01 0.1 1 10 100 Favours [SNRI] Favours [Placebo]

Figure 15.3 SNRI (Duloxetine) versus placebo; Adverse Event: Constipation

	Duloxe	tine	Placel	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% C	M-H, Random, 95% Cl
Konno 2016	25	232	5	226	49.6%	4.87 [1.90, 12.50]	
Skljarevski 2010	10	198	8	203	50.4%	1.28 [0.52, 3.18]	
Total (95% CI)		430		429	100.0%	2.48 [0.66, 9.31]	
Total events	35		13				
Heterogeneity: Tau ² =	0.69; Chi ²	= 4.08,	df = 1 (P	= 0.04); l² = 75%)	
Test for overall effect:	Z = 1.35 (l	P = 0.18	3)				0.1 0.2 0.5 1 2 5 10 Favours SNRI Favours Placebo


Figure 15.4 SNRI (Duloxetine) versus placebo; Adverse Event: Dizziness

	Duloxe	tine	Place	bo		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
Skljarevski 2010	8	198	2	203	47.6%	4.10 [0.88, 19.07]	
Konno 2016	15	232	2	226	52.4%	7.31 [1.69, 31.59]	_ →
Total (95% CI)		430		429	100.0%	5.55 [1.92, 16.02]	
Total events	23		4				
Heterogeneity: Tau ² =				= 0.59); I² = 0%		1 0.1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 3.17 (I	P = 0.00	02)				Favours SNRI Favours Placebo

Figure 15.5 SNRI (Duloxetine) versus placebo; Adverse Event: Dry Mouth


	Duloxe	tine	Place	00		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	I M-H, Random, 95% CI
Konno 2016	14	232	0	226	35.5%	28.25 [1.70, 470.82]	
Skljarevski 2010	12	198	4	203	64.5%	3.08 [1.01, 9.38]	
Total (95% CI)		430		429	100.0%	6.76 [0.68, 67.37]	
Total events	26		4				
Heterogeneity: Tau ² =	1.81; Chi ²	= 2.52	df = 1 (P	= 0.11); I ² = 60%		1 1 0.2 0.5 1 2 5 10
Test for overall effect:	Z = 1.63 (I	P = 0.10	0)				0.1 0.2 0.5 1 2 5 10 Favours SNRI Favours Placebo


Figure 15.6 SNRI (Duloxetine) versus placebo; Adverse Event: Nausea




Funnel Plots


Funnel plots were generated via RevMan for interventions with ≥ 8 studies. This information was used in the GRADE process to assess potential publication bias.






Smaller studies appear to be missing to the left of the effect line which may suggest some publication bias, but otherwise well balanced.





Smaller and larger studies appear to be missing to the left of the effect line which suggests publication bias.

Figure 17.3 Corticosteroid Injection studies



Funnel plot appears balanced. No suggestion of publication bias.

Quality Assessment

Cochrane Risk of Bias Tables

The Cochrane Risk of Bias is an assessment tool that addresses seven specific domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and other bias. Due to the subjective nature of the outcomes, we chose to split the 'blinding of participants and personnel' domain and use the 'other bias' domain specifically for blinding of personnel. Each domain was assigned a judgement related to the risk of bias, specifically 'low', 'high' or 'unclear' risk of bias.

Determining Risk of Bias Median

To generate the meta-analyses that utilized a risk of bias median we assigned a quality score to each risk domain highlighted in the Cochrane Risk of Bias tool. Assignment is outlined as follows: (Low Risk = 0, Unclear Risk = 1, High Risk = 2). Each study had their domain assigned a number and the sum was found for each study. We determined the median and divided studies into two subgroups: Less than the median and Equal to or greater than the median.

Table 8.1 Exercise






Table 8.2 Acupuncture








Table 8.4 Oral NSAIDs




Table 8.5 Rubefacients




Table 8.6 Opioids




Table 8.7 SNRI (Duloxetine)




Table 8.8 Corticosteroid injections




Table 9: GRADE Evaluation of Evidence Quality

Intervention	Number of RCTs	Risk Ratio	Reasons for Downgrading	Certainty in Evidence
Exercise	19	RR 1.71 (95% Cl 1.37, 2.15)	Risk of Bias (-1)	Moderate
Oral NSAIDs	4	RR 1.44 (95% Cl 1.17, 1.78)	Risk of Bias (-1)	Moderate
SNRI (duloxetine)	4	RR 1.25 (95% Cl 1.13, 1.38)	Risk of Bias (-1)	Moderate
Spinal Manipulation	5	RR 1.54 (95% Cl 1.11, 2.12)	Risk of Bias (-1) Inconsistency (-1)	Low
Rubefacients	3	RR 1.39 (95% Cl 1.20, 1.61)	Risk of Bias (-1) Indirectness (-1)	Low
Acupuncture	10	RR 1.58 (95% Cl 1.13, 2.21)	Risk of Bias (-1) Inconsistency (-1) Publication Bias (-1)	Very low
Opioids	6	RR 1.26 (95% Cl 1.02, 1.55)	Risk of Bias (-1) Indirectness (-1) Imprecision (-1)	Very low
Corticosteroid Injections	10	RR 1.07 (95% CI 0.87, 1.30)	Risk of Bias (-1) Inconsistency (-1) Imprecision (-1)	Very low

Ordered Interventions by Certainty in Evidence Followed by Highest Risk Ratio to Lowest Risk Ratio.

RCTs: Randomized Controlled Trials; RR: Risk Ratio; Cl: Confidence Interval; RR: Risk Ratio NSAIDs: Nonsteroidal Anti-Inflammatory drugs SNRIs: Serotonin Norepinephrine Reuptake Inhibitor

GRADE Criteria for Quality Assessment Sections

	Consider allocation concealment, blinding, large losses to follow-up, ITT analysis, stopping early for									
Risk of Bias	benefit, etc.									
	Failure to report outcomes/selective reporting of outcomes									
Inconsistency	Do the estimates of the treatment effect vary widely across studies?									
inconsistency	Statistical heterogeneity, variability in results									
	Unexplained inconsistency/heterogeneity $ ightarrow$ decreased quality									
	Differences in population (i.e. patients or animal studies)									
Indirectness	Differences in intervention (i.e. method or timing of delivery)									
	Differences in outcome measures (i.e. surrogates or length of time)									
	Indirect comparison (i.e. network meta-analyses)									
Imprecision	Does confidence interval cross threshold for clinical decision making?									
	Wide confidence intervals (few patients, few events)									
Publication	Small number of trials									
bias	Only industry funded trials included									
	Funnel plot									
Magnitude	Large and consistent estimates of the magnitude of a treatment effect									
of effect	Large effect: RR >2 or <0.5; very large effect: RR >5 or <0.2									
Dose										
response	Presence of this gradient increases the confidence.									
gradient										
Plausible	If residual confounding would be expected to bias the treatment effect in the opposite direction as									
confounding	observed - increases confidence in results.									
	emann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of 5. Updated October 2013. The GRADE Working Group, 2013. Available from <u>guidelinedevelopment.org/handbook</u> .									

Peer Review Comments/Feedback

Peer Reviewer Information

5 reviewers including family physicians and allied health care professionals *NO competing conflicts of interest declared

Strengths of the Systematic Review

This is an exceptionally good and helpful review of a common issue in primary care, low back pain. This review focuses on single interventions and included RCTs of adults with chronic (greater than 90 days) radicular or non-radicular low back pain. A list of pharmacological and non-pharmacological interventions are utilized with the primary outcome being a 30% reduction in pain. Multiple databases were used to search a large number of articles with 61 articles in the final review. The a-priori analyses to explore funding sources and duration of outcomes reported was a strength as was the examination of low back pain in a primary care setting. It was interesting to note acetaminophen, cannabinoids, muscle relaxants, SSRIs or TCAs did not meet inclusion criteria with an opportunity for future research.

Broad, looking at more or less every possible intervention out there. Sensitivity analyses were established a priori. Meta-analysis was done on an easily translatable outcome, that being percentage of patients who responded meaningfully, not some esoteric pain or function scale that means nothing to anyone.

Overall, congrats to the team on this excellent work. I appreciate the massive amount of work that goes into a SR/MA on one topic, let alone 15 in a review like this. However, I do have a few comments for the author team to consider... I think a main strength is that the process used in the review appears credible. - Inclusion criteria – RCT, Responder analysis - Primary Studies assessed for risk of bias - Pre-specified analysis to explore heterogeneity - Use of the GRADE approach to determine Confidence in estimates.

Strengths of the systemic review are the breadth of articles reviewed and the choice of commonly used and commonly available treatment modalities. Limitation to responder analysis increases the strength of conclusions for a particular modality. The use of NNT's and NNH's as descriptors is for me, valuable. The use of the tables and forest plots is visually helpful.

Sufficient number of studies reviewed reasonable conclusions based on evidence reviewed.

Weaknesses of the Systematic Review

As noted in the limitations section of the manuscript, the decision to combine heterogeneous interventions into one intervention category and the relatively few RCT's utilizing responder analysis are the weakness of this review. The diverse factors, subjective nature and varying responses to low back pain could be considered a challenge and weakness.

I was somewhat concerned that some of the questions addressed in the SR/MA may be a bit broad and because different interventions were combined the analyses display high heterogeneity (e.g., combining all exercise interventions: I2 = 75%;)

Authors' response: Manuscript revised. We felt that in an effort to limit additional sub-group analysis (and the risk of chance findings), that grouping potentially heterogenous non-pharmacological and pharmacological interventions was appropriate for this review. Whether groups that choose to sub-

group interventions (e.g. different types of exercise or different classes of NSAIDs) find consistent and reliable, or inconsistent and confusing results remains to be seen.

Potentially the broad scope of the SR is a weakness, as stated in the discussion. Given the screening process and inclusion criteria of trials, it's likely any weakness that might have come from that was effectively mitigated.

Search: Search appears quite comprehensive (but others (Ioannidis see below) have included other databases (Central, Cinhal, Psychinfo, Lilacs)

Authors' response: Manuscript modified. Cochrane database was formally named "Central" and was included in search. Cinhal, Psychinfo and Lilacs databases were not applicable for this review.

Context: The paper lacks context about other existing reviews and guideline recommendations for the interventions reviewed. (Introduction and discussion section). A cursory search shows that several individual SR/MA have been done on the interventions included in this review.

- https://pubmed.ncbi.nlm.nih.gov/25681408/
- <u>https://pubmed.ncbi.nlm.nih.gov/26863524/</u>
- https://pubmed.ncbi.nlm.nih.gov/18253994/

o Also, it seems other papers have combined several SR/MA like done in this paper https://pubmed.ncbi.nlm.nih.gov/30563712/

o How do the findings compare to previous reviews (particularly those that focused on SMD?) Authors' response: Manuscript modified

o What specifically does this paper add to the large body of existing reviews? Authors' response: Manuscript modified. Our systematic review was the first synthesis of multiple (15) different interventions for chronic low back pain that was led by primary care, reported outcomes through responder analysis, and included robust reporting of adverse events.

In the discussion section the short-term benefits of a modality eg. acupuncture <4 weeks may be helpful to point out to a greater extend as clinicians often separate short term and long-term management modalities in assessing their armamentarium for a condition. (listed line 234, 235) Authors' response: This review focused on chronic (≥3 months) low back pain. Whether findings should be re-analyzed into interventions that may be most effective for 'early' chronic low back pain (e.g. 3-6 months) or 'late' chronic low back pain (e.g. >6 months) will be forwarded to our chronic pain guideline committee.

Not sure if possible to separate out back pain studies done in chronic back pain aimed at return to work only -done by employers (probably future work/ review). Wondering if in return to work there is a greater problem than return to function in non-work groups? Authors' response: Beyond the scope of this systematic review.

Comments, considerations or changes

1. Publication Bias: 3 Funnel plots are presented in figures 17.1-17.3. but the manuscript is missing a description of how publication bias was assessed, the results of these assessments, and a conclusion regarding how publication bias affects confidence.

Authors' response: Manuscript and Appendix modified

2. Limitations: Given this is a paper that combines 15 different systematic reviews, I was watching to see if the any comments were going to be made about the comparative efficacy of the different interventions. It appears that the authors have avoided this temptation, although it was hard as a reader to not make comparisons between the interventions based on the way the manuscript is presented, which is not really appropriate based on the design (not a network MA). Address problem more head on in the limitations. It appears John Ioannides and his group are doing a SR & network MA of drug and non-drug interventions for chronic low back pain which will address these indirect comparisons. o https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01398-3

Authors' response: Addressed in knowledge translation tool (which was not available at time of manuscript peer review)

Comments: Overall great article to better alter poor management habits or support good management habits in a problem that is huge in primary care. Thanks for your effort.

Line 29 - you may define in brackets a rubefacient - not a common term used in general practice. Authors' response: Manuscript modified

Line 123 Would it be helpful as a comparator to have NNH of oral NSAID's, as adverse effects often quoted as reason not to use and this review suggests some benefit? Authors' response: NNH was not calculated due to no statistical difference between NSAIDs and placebo in withdrawals due to adverse events.

No specific comments, helpful review for family physicians, confirms my clinical experience, though the use of SNRI's is interesting and not common practice in my experience

References

Acupuncture

- 1. Brinkhaus B, Witt CM, Jena S, et al. Acupuncture in patients with chronic low back pain: a randomized controlled trial. 2006;166(4):450-457.
- 2. Cherkin DC, Sherman KJ, Avins AL, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. 2009;169(9):858-866.
- 3. Coan RM, Wong G, Ku SL, et al. The acupuncture treatment of low back pain: a randomized controlled study. 1980;8(1-2):181-189.
- 4. Haake M, Müller HH, Schade-Brittinger C, et al. German Acupuncture Trials (GERAC) for chronic low back pain: randomized, multicenter, blinded, parallel-group trial with 3 groups. 2007;167(17):1892-1898.
- 5. Hunter RF, McDonough SM, Bradbury I, et al. Exercise and auricular acupuncture for chronic low-back pain: A feasibility randomized-controlled trial. *The Clinical Journal of Pain.* 2011.
- 6. Kerr DP, Walsh DM, Baxter D. Acupuncture in the management of chronic low back pain: a blinded randomized controlled trial. 2003;19(6):364-370.
- 7. Meng CF, Wang D, Ngeow J, Lao L, Peterson M, Paget S. Acupuncture for chronic low back pain in older patients: a randomized, controlled trial. 2003;42(12):1508-1517.
- 8. Molsberger A, Winkler J, Schneider S, Mau J. Acupuncture and conventional orthopedic pain treatment in the management of chronic low back pain a prospective randomised and controlled clinical trial. 1998(june):87.
- Qin Z, Ding Y, Xu C, et al. Acupuncture vs Noninsertive Sham Acupuncture in Ageing Patients with Degenerative Lumbar Spinal Stenosis: a Randomized Controlled Trial. 2019.
- 10. Witt CM, Jena S, Selim D, et al. Pragmatic randomized trial evaluating the clinical and economic effectiveness of acupuncture for chronic low back pain. 2006;164(5):487-496.

Anticonvulsants

11. Atkinson JH, Slater MA, Capparelli EV, et al. A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating component. 2016;157(7):1499-1507.

Corticosteroid Injections

- 12. Arden NK, Price C, Reading I, et al. A multicentre randomized controlled trial of epidural corticosteroid injections for sciatica: The WEST study. *Rheumatology.* 2005;44(11):1399-1406.
- 13. Carette S, Leclaire R, Marcoux S, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. *New England Journal of Medicine*. 1997;336(23):1634-1640.
- 14. Ghahreman A, Ferch R, Bogduk N. The efficacy of transforaminal injection of steroids for the treatment of lumbar radicular pain. *Pain medicine (Malden, Mass)*. 2010;11(8):1149-1168.

- 15. Ghai B, Kumar K, Bansal D, Dhatt SS, Kanukula R, Batra YK. Effectiveness of parasagittal interlaminar epidural local anesthetic with or without steroid in chronic lumbosacral pain: A randomized, double-blind clinical trial. *Pain Physician.* 2015;18(3):237-248.
- 16. Manchikanti L, Cash KA, McManus CD, Pampati V. Fluoroscopic caudal epidural injections in managing chronic axial low back pain without disc herniation, radiculitis, or facet joint pain. 2012;5:381-390.
- 17. Manchikanti L, Cash KA, McManus CD, Pampati V, Fellows B. Fluoroscopic caudal epidural injections with or without steroids in managing pain of lumbar spinal stenosis: One-year results of randomized, double-blind, active-controlled trial. *Journal of Spinal Disorders and Techniques.* 2012;25(4):226-234.
- 18. Manchikanti L, Cash KA, Pampati V, Falco FJE. Transforaminal epidural injections in chronic lumbar disc herniation: A randomized, double-blind, active-control trial. *Pain Physician.* 2014;17(4):E489-E501.
- 19. Ng L, Chaudhary N, Sell P. The efficacy of corticosteroids in periradicular infiltration for chronic radicular pain: a randomized, double-blind, controlled trial. 2005;30(8):857-862.
- 20. Nguyen C, Boutron I, Baron G, et al. Intradiscal Glucocorticoid Injection for Patients With Chronic Low Back Pain Associated With Active Discopathy: a Randomized Trial. 2017;166(8):547-556.
- 21. Saqib M, Bhatti SN, Khan MA, et al. Outcome Analysis Of Two Different Injection Solutions For Epidural Injection In Radicular Lumbar Backache Syndromes. *Journal of Ayub Medical College, Abbottabad : JAMC.* 2016;28(4):709-714.

Exercise

- 22. Albaladejo C, Kovacs FM, Royuela A, del Pino R, Zamora J. The efficacy of a short education program and a short physiotherapy program for treating low back pain in primary care: a cluster randomized trial. 2010;35(5):483-496.
- 23. Brandt Y, Currier L, Plante TW, Schubert Kabban CM, Tvaryanas AP. A Randomized Controlled Trial of Core Strengthening Exercises in Helicopter Crewmembers with Low Back Pain. 2015;86(10):889-894.
- 24. Brodsky M, Hansen A, Bjerke W. Randomized Pilot Trial for a Community-Based Group Stretching Exercise Program for Chronic Low Back Pain. 2019;8.
- 25. Chan AYP, Ford JJ, Surkitt LD, et al. Individualised functional restoration plus guidelinebased advice vs advice alone for non-reducible discogenic low back pain: a randomised controlled trial. 2017;103(2):121-130.
- 26. Costa LO, Maher CG, Latimer J, et al. Motor control exercise for chronic low back pain: a randomized placebo-controlled trial. 2009;89(12):1275-1286.
- 27. Cox H, Tilbrook H, Aplin J, et al. A randomised controlled trial of yoga for the treatment of chronic low back pain: results of a pilot study. 2010;16(4):187-193.
- 28. Ford JJ, Hahne AJ, Surkitt LD, et al. Individualised physiotherapy as an adjunct to guideline-based advice for low back disorders in primary care: a randomised controlled trial. 2016;50(4):237-245.
- 29. Frost H, Lamb SE, Doll HA, Carver PT, Stewart-Brown S. Randomised controlled trial of physiotherapy compared with advice for low back pain. 2004;329(7468):708.

- 30. Groessl EJ, Liu L, Chang DG, et al. Yoga for Military Veterans with Chronic Low Back Pain: a Randomized Clinical Trial. 2017;53(5):599-608.
- 31. Hall AM, Maher CG, Lam P, Ferreira M, Latimer J. Tai chi exercise for treatment of pain and disability in people with persistent low back pain: a randomized controlled trial. 2011;63(11):1576-1583.
- 32. Hartvigsen J, Morsø L, Bendix T, Manniche C. Supervised and non-supervised Nordic walking in the treatment of chronic low back pain: a single blind randomized clinical trial. 2010;11:30.
- Highland KB, Schoomaker A, Rojas W, et al. Benefits of the Restorative Exercise and Strength Training for Operational Resilience and Excellence Yoga Program for Chronic Low Back Pain in Service Members: a Pilot Randomized Controlled Trial. 2018;99(1):91-98.
- 34. Jensen RK, Leboeuf-Yde C, Wedderkopp N, Sorensen JS, Manniche C. Rest versus exercise as treatment for patients with low back pain and Modic changes. A randomized controlled clinical trial. 2012;10:22.
- 35. Moffett JK, Torgerson D, Bell-Syer S, et al. Randomised controlled trial of exercise for low back pain: clinical outcomes, costs, and preferences. 1999;319(7205):279-283.
- 36. Natour J, Cazotti Lde A, Ribeiro LH, Baptista AS, Jones A. Pilates improves pain, function and quality of life in patients with chronic low back pain: a randomized controlled trial. 2015;29(1):59-68.
- 37. Saper RB, Lemaster C, Delitto A, et al. Yoga, Physical Therapy, or Education for Chronic Low Back Pain: a Randomized Noninferiority Trial. 2017;167(2):85-94.
- 38. Saper RB, Sherman KJ, Cullum-Dugan D, Davis RB, Phillips RS, Culpepper L. Yoga for chronic low back pain in a predominantly minority population: a pilot randomized controlled trial. 2009;15(6):18-27.
- Sherman KJ, Cherkin DC, Erro J, Miglioretti DL, Deyo RA. Comparing yoga, exercise, and a self-care book for chronic low back pain: a randomized, controlled trial. 2005;143(12):849-856.
- 40. Sherman KJ, Cherkin DC, Wellman RD, et al. A randomized trial comparing yoga, stretching, and a self-care book for chronic low back pain. 2011;171(22):2019-2026.

Opioids

- 41. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. 2010;11(11):1787-1804.
- 42. Christoph A, Eerdekens MH, Kok M, Volkers G, Freynhagen R. Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial. 2017;158(9):1813-1824.
- 43. Lee JH, Lee C-S, Ultracet ERSG. A randomized, double-blind, placebo-controlled, parallelgroup study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain. *Clinical therapeutics.* 2013;35(11):1830-1840.

- 44. Peloso PM, Fortin L, Beaulieu A, Kamin M, Rosenthal N. Analgesic efficacy and safety of tramadol/ acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. 2004;31(12):2454-2463.
- 45. Ruoff GE, Rosenthal N, Jordan D, Karim R, Kamin M. Tramadol/acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. 2003;25(4):1123-1141.
- 46. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. 2012;28(10):1617-1634.

Oral NSAIDs

- 47. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.
 2004;26(8):1249-1260.
- 48. Katz N, Borenstein DG, Birbara C, et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. 2011;152(10):2248-2258.
- 49. Katz N, Ju WD, Krupa DA, et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: Results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. *Spine.* 2003;28(9):851-858.
- Katz N, Rodgers DB, Krupa D, Reicin A. Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials. 2004;20(5):651-658.
- 51. Kivitz AJ, Gimbel JS, Bramson C, et al. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. 2013;154(7):1009-1021.

Rubefacients

- 52. Chrubasik S, Weiser T, Beime B. Effectiveness and safety of topical capsaicin cream in the treatment of chronic soft tissue pain. 2010;24(12):1877-1885.
- 53. Frerick H, Keitel W, Kuhn U, Schmidt S, Bredehorst A, Kuhlmann M. Topical treatment of chronic low back pain with a capsicum plaster. 2003;106(1-2):59-64.
- 54. Keitel W, Frerick H, Kuhn U, Schmidt U, Kuhlmann M, Bredehorst A. Capsicum pain plaster in chronic non-specific low back pain. 2001;51(11):896-903.

SNRI (duloxetine)

- Konno S, Oda N, Ochiai T, Alev L. Randomized, Double-blind, Placebo-controlled Phase III Trial of Duloxetine Monotherapy in Japanese Patients With Chronic Low Back Pain. 2016;41(22):1709-1717.
- 56. Skljarevski V, Desaiah D, Liu-Seifert H, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. 2010;35(13):E578-585.
- Skljarevski V, Ossanna M, Liu-Seifert H, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. 2009;16(9):1041-1048.

58. Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. 2010;11(12):1282-1290.

Spinal Manipulation

- 59. Bialosky JE, George SZ, Horn ME, Price DD, Staud R, Robinson ME. Spinal manipulative therapy-specific changes in pain sensitivity in individuals with low back pain (NCT01168999). 2014;15(2):136-148.
- 60. Bond BM, Kinslow CD, Yoder AW, Liu W. Effect of spinal manipulative therapy on mechanical pain sensitivity in patients with chronic nonspecific low back pain: a pilot randomized, controlled trial. *The Journal of manual & manipulative therapy.* 2020;28(1):15-27.
- 61. Ford JJ, Slater SL, Richards MC, et al. Individualised manual therapy plus guideline-based advice vs advice alone for people with clinical features of lumbar zygapophyseal joint pain: a randomised controlled trial. 2019;105(1):53-64.
- 62. Goertz CM, Salsbury SA, Long CR, et al. Patient-centered professional practice models for managing low back pain in older adults: a pilot randomized controlled trial. 2017;17(1):235.
- 63. Licciardone JC, Aryal S. Clinical response and relapse in patients with chronic low back pain following osteopathic manual treatment: results from the OSTEOPATHIC Trial. 2014;19(6):541-548.
- 64. Licciardone JC, Gatchel RJ, Aryal S. Recovery From Chronic Low Back Pain After Osteopathic Manipulative Treatment: a Randomized Controlled Trial. 2016;116(3):144-155.
- 65. Licciardone JC, Gatchel RJ, Aryal S. Targeting Patient Subgroups With Chronic Low Back Pain for Osteopathic Manipulative Treatment: responder Analyses From a Randomized Controlled Trial. 2016;116(3):156-168.
- 66. Licciardone JC, Kearns CM, Minotti DE. Outcomes of osteopathic manual treatment for chronic low back pain according to baseline pain severity: results from the OSTEOPATHIC Trial. 2013;18(6):533-540.
- 67. Licciardone JC, Minotti DE, Gatchel RJ, Kearns CM, Singh KP. Osteopathic manual treatment and ultrasound therapy for chronic low back pain: a randomized controlled trial. 2013;11(2):122-129.

Topical NSAIDs

68. Nct. Flurbiprofen Tape for Treatment of Chronic Low Back Pain. 2008.